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1. ABSTRACT/RESUMEN 
1.1. ABSTRACT 
1.1.1. Background  
The parasitic infection toxoplasmosis has been suggested as a possible etiologic agent 
of epilepsy of unknown origin and other neuropsychiatric diseases. In recent years there 
is increased evidence of the relation of T. gondii acquired infection in non-
inmunodeficient subjects with epilepsy. But studies in children are scarce and with 
contradictory results. A case-control study has been conducted to investigate the 
hypothesis that Libyan children with cryptogenic epilepsy have a higher prevalence of 
seropositivity to T. gondii than the control population. 
1.1.2. Objectives: 
The main objective of the study was to evaluate the relationship between cryptogenic 
epilepsy and toxoplasmosis in Libyan children. The secondary objectives were to assess 
the toxoplasmosis relationships with seizure types and seizure control and to identify 
behavioural risk factors for acquired toxoplasmosis in Libyan children. 
1.1.3. Methods 
Study Design: hospital-based, case-controlled study. 
Setting: National Centre for Treatment of Epilepsy and Tripoli Medical Centre, Tripoli, 
Libya.  
Subjects: The target population were cryptogenic epilepsy from (National Epileptic 
Centre). Control groups (symptomatic epilepsy and non-epileptic children) were taken 
from National Epileptic Centre and Tripoli Medical Centre. 
A total of 298 children were recruited over a one-year period. The group of cases were 
92 children with suspected cryptogenic epilepsy. Two control groups included 56 
children with symptomatic epilepsy and 150 children without epilepsy. The ages ranged 
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from 6 to 17 years. The children were surveyed with a questionnaire given to each 
child's parent or legal guardian. Blood samples were studied for the presence of IgG 
anti-Toxoplasma antibodies. 
1.1.4. Results:  
A total of 298 children were included with mean age 11.14 ± 3.25 years (range, 6– 17.5 
years). Were classified in three groups as suspected cryptogenic epilepsy (case, n = 92; 
54 male and 38 female) and two controls; symptomatic epilepsy (n = 56; 35 male and 
21 female) and non-epileptic (n = 150; 81 male and 69 female) were enrolled in the 
study. Residence was urban, suburban and rural in 29%, 32% and 39% respectively. 
The seropositivity rate for anti-Toxoplasma IgG antibodies among suspected 
cryptogenic epilepsy patients (35.2%) was not statistically different of symptomatic 
epilepsy (29.4%) and non-epileptic children (29%). There were a significant difference 
between mean of anti-Toxoplasma (IgG) titters in cryptogenic epilepsy (24.7±8.4 
IU/mL) and those in symptomatic epilepsy (15.3±5.8 IU/mL) and non-epileptic subjects 
(16.1±4 IU/mL) (p< 0.05). High anti-T. gondii IgG titters (>75 IU/mL) were 
significantly more frequent in cryptogenic than symptomatic epilepsy children and non-
epileptic control (17.4% versus 6.7%, 6.6%; p< 0.05). 
On the other hand, prevalence of T. gondiii infection was higher in children with focal 
seizures than in those with generalized seizures and non-epileptic controls (47.1%, 25% 
and 29.4% respectively; p<0.01). Logistic regression analysis; confirmed that focal 
seizures were only epilepsy subtype positively associated with toxoplasmosis (OR = 
2.32; 95% CI: 1.25–4.32; p <0.01).  
Behavioral factors related with T. gondii infection, were identified by bivariate and 
multivariate analysis. Variables related to increased risk for toxoplamosis were eating 
raw meat (OR 3.16), eating raw vegetables (OR 4.02), contact with soil (OR 3.46), 
house cat and neighbourhood cat (OR 2.8 and 4.12 respectively) (all p<0.01). Drinking 
water from wells and rain deposits was negatively related with toxoplasmosis (OR 
0.37). 
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1.1.5. Conclusions  
There were no significant differences in the prevalence of anti-T. gondii antibodies 
among patients with cryptogenic epilepsy and controls. However, patients with 
cryptogenic epilepsy had higher antibody titers than the other groups and higher 
frequency of subjects with high titers of anti-Toxoplasma IgG. These latter findings 
may suggest a certain relationship between T. gondii infection and cryptogenic epilepsy. 
A higher prevalence of anti-Toxoplasma antibodies was found in children with focal 
epilepsy than in patients with generalized epilepsy and non-epileptic controls, 
suggesting a relationship between focal epilepsy and acquired toxoplasmosis. T. gondii 
infection was not found to influence the control of epilepsy. Eating undercooked meat, 
raw vegetables, contact with the soil and contact with cats were related to the 
acquisition of toxoplasmosis. 
Based on these results, it can be concluded that Toxoplasma gondii infection may play 
some pathogenic role in focal epilepsy and perhaps also in cryptogenic epilepsy. The 
impact of toxoplasmosis-related epilepsy should be evaluated and taken into account in 
order to design optimal preventive measures against T. Gondii infection in Libya. 
1.1.6. Key words 
Toxoplasmosis, Toxoplasma gondii, epilepsy, cryptogenic epilepsy, focal seizures, 
seroprevalence, risk factors, antibody titers, IgG, children, adolescents, Libya, Libyan 
epileptic children, Tripoli, North Africa. 
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1.2. RESUMEN 
1.2.1. Antecedentes 
La toxoplasmosis adquirida ha sido sugerida como una posible etiología de la epilepsia 
de origen desconocido y otras enfermedades neuropsiquiátricas. En los últimos años se 
incrementa la evidencia de la relación entre la infección adquirida por T. gondii en 
sujetos no inmunodeficientes con la epilepsia. No obstante, los estudios en niños son 
escasos y con resultados contradictorios. Se ha realizado un estudio caso-control para 
investigar la hipótesis de que los niños libios con epilepsia criptogénica tienen una 
mayor prevalencia de seropositividad frente a T. gondii que la población de control. 
1.2.2. Objetivos: 
El objetivo principal del estudio fue evaluar la posible relación entre la epilepsia 
criptogénica y la toxoplasmosis en niños libios. Los objetivos secundarios fueron 
evaluar las relaciones de toxoplasmosis con los tipos de convulsiones y el control de las 
crisis e identificar los comportamientos que constituían factores de riesgo para la 
toxoplasmosis adquirida en niños libios. 
1.2.3. Métodos 
Diseño del estudio: estudio clínico basado en un caso controlado. 
Lugar: National Centre for Treatment of Epilepsy and Tripoli Medical Centre, Tripoli, 
Libya.  
Sujetos: La población diana fue pacientes pediátricos con sospecha de epilepsia 
criptogénica (National Centre for Treatment of Epilepsy). Los grupos de control 
(epilepsia sintomática y niños no epilépticos) fueron recogidos en el National Centre for 
Treatment of Epilepsy y el Tripoli Medical Centre.  
Un total de 298 niños fueron reclutados en un período de un año. El grupo de casos 
fueron 92 niños con sospecha de epilepsia criptogénica. Los dos grupos de control 
incluyeron a 56 niños con epilepsia sintomática y a 150 niños sin epilepsia. Las edades 
comprendían de 6 a 17 años. Los niños fueron entrevistados con un cuestionario 
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entregado a los padres de cada niño o a su tutor legal. Se estudiaron muestras de sangre 
para detectar la presencia de anticuerpos IgG anti-Toxoplasma. 
1.2.4. Resultados 
Se incluyeron 298 niños con edad media de 11,14 ± 3,25 años (rango, 6- 17,5 años). Se 
clasificaron en tres grupos, pacientes con sospecha de epilepsia criptogénica (casos, n = 
92; 54 hombres y 38 mujeres) y dos grupos de control de niños con epiilepsia 
sintomática (n = 56, 35 hombres y 21 mujeres) y no epilépticos (n = 150, 81 hombres y 
69 mujeres). El lugar de residencia fue en zona urbana, suburbana y rural en el 29%, 
32% y 39% respectivamente.  
La tasa de seropositividad de los anticuerpos anti-Toxoplasma IgG entre los pacientes 
con sospecha de epilepsia criptogénica (35,2%) no fue estadísticamente diferente de los 
pacientes con epilepsia sintomática (29,4%) y los controles no epilépticos 
(29,4%). Hubo diferencias significativas entre los títulos de IgG anti-Toxoplasma entre 
los pacientes con epilepsia criptogénica (24,7 ± 8,4 UI / ml) y los que presentaban 
epilepsia sintomática (15,3 ± 5,8 UI/mL) y los controles no epilépticos (16,1 ± 4 
UI/mL) (p< 0,05). Los títulos altos de IgG anti-T. Gondii (>75 UI/ml) fueron 
significativamente más frecuentes en niños con epilepsia criptogénica que en niños con 
epilepsía sintomática y en controles no epilépticos (17,4% versus 6,7% y 6,6%, p 
<0,05). 
Por otro lado, la prevalencia de infección por T. gondiii fue mayor en niños con 
convulsiones focales que en aquellos con convulsiones generalizadas y controles no 
epilépticos (47,1%, 25% y 29,4% respectivamente, p <0,01). El análisis de regresión 
logística confirmó que las convulsiones focales eran el único subtipo de epilepsia 
positivamente asociado con toxoplasmosis (OR = 2,32; IC 95%: 1,25-4,32; p <0,01). 
Los factores conductuales relacionados con la infección por T. gondii, se identificaron 
por análisis bivariado y multivariante. Las variables relacionadas con un mayor riesgo 
de toxoplasmosis fueron comer carne cruda o poco cocinada (OR 3,16), comer verduras 
crudas (OR 4,02), contacto con suelo (OR 3,46), gato doméstico y gato en el vecindario 
(OR 2,8 y 4,12 respectivamente) (p <0,01). Obtener el agua para beber de pozos y 
depósitos de lluvia se relacionó negativamente con la toxoplasmosis (OR 0,37). 
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1.2.5. Conclusiones 
No se encontraron diferencias significativas en la prevalencia de anticuerpos anti T. 
gondii entre los pacientes con epilepsia criptogénica y los controles. Sin embargo, los 
pacientes con epilepsia criptogénica tuvieron títulos de anticuerpos más elevados que 
los otros grupos y mayor frecuencia de sujetos con títulos altos de IgG anti-
Toxoplasma. Estos últimos hallazgos pueden sugerir una cierta relación entre la 
infección por T. gondii y la epilepsia criptogénica. 
Se encontró una mayor prevalencia de anticuerpos anti toxoplasma en los niños con 
epilepsia focal que en los pacientes con epilepsia generalizada y los controles no 
epilépticos, lo que sugiere una relación entre la epilepsia focal y la toxoplasmosis 
adquirida. No se encontró que la infección por T. gondii influyera en el control de la 
epilepsia. El comer carne poco cocinada, comer vegetales crudos, el contacto con el 
suelo y el contacto con gatos se relacionaron con la adquisición de toxoplasmosis. 
Basándose en estos resultados, se puede concluir que la infección por Toxoplasma 
gondii puede desempeñar un papel etiopatogénico en la epilepsia focal y quizás también 
en la criptogénica. El impacto de la epilepsia relacionada con la toxoplasmosis debe ser 
evaluado y tomado en cuenta para diseñar medidas preventivas óptimas contra la 
infección por T. Gondii en Libia. 
1.2.6. Palabras clave 
Toxoplasmosis, Toxoplasma gondii, epilepsia, epilepsia criptogénica, convulsiones 
focales, seroprevalencia, factores de riesgo, títulos de anticuerpos, IgG, niños, 
adolescentes, Libia, niños epilépticos libios, Trípoli, África del Norte. 
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2. INTRODUCTION AND BACKGROUND 
2.1. Background and Rationale for the study  
Toxoplasmosis is one of the most common zoonotic infections that is prevalent 
worldwide, caused by the protozoa parasite Toxoplasma Gondi (Dubey and Beatie, 
1988). The infection not only affects animal’s health, causing production and economic 
loss, but also continues to be a global human health risk (Tenter et al., 2000).  
The sero-prevelance varies widely in different regions in the world, but is particularly 
prevalent in Europe, South America, and Africa (Petersen 2007). The prevalence is 
influenced by geography, environmental conditions, as well as cultural habits and the 
hygiene of people (Dubey and Beatie, 1988). The infection can be acquired by 
accidental ingestion of contaminated food or water with infective oocycts seeded by 
cats, by tissue cysts in raw or undercooked meat or transplacentally to the fetus during 
pregnancy (Dubey and Beatie, 1988).  
Clinical symptoms of toxoplasmosis can vary. Eighty per cent of  primary infections are 
asymptomatic and on the opposite, symptoms may be chronic making clinical diagnosis 
difficult (Studenicova et al., 2006). The clinical diagnosis must therefore be supported 
by a serological test.  
Treatment includes antibiotics, folinic acid and corticosteroids. The infection can be 
particularly severe in those with immune deficits, and in babies who are congenitally 
infected. Prevention and education strategies are the key to avoiding future outbreaks 
(Dubey and Beatie, 1988).  
Congenital toxoplasmosis is clearly related with certain neurological disorders such as 
seizures, blindness, mental retardation, hydrocephaly, cerebral palsy and nerve deafness 
(Roizen et al. 1995). The impact of acquired toxoplasmosis on neurological diseases is 
still not clear. Epidemiological surveys have reported that the prevalence of epilepsy in 
developing countries is higher  than in  industrialized countries (Senanayake and 
Roman, 1993), suggesting a role for infective aetiologies. Some studies have shown that 
a definitive infective aetiology of epilepsy can be determined in about 50% of all newly 
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diagnosed cases (Annegers et al., 1996). However, little is known about the potential 
etiological role of this protozoan in epilepsy.  
A few studies have shown to be an association between latent acquired toxoplasmosis 
and the development of epilepsy (Yazar et al., 2003, Palmer, 2007.). Understanding the 
association between toxoplasmosis and epilepsy could be an important step in future 
efforts to reduce and prevent epilepsy and other learning difficulties in low resource 
epilepsy settings.                       
2.2. Purpose of the study 
Probably the  Toxoplasma Gondii infection has an association with epilepsy, either as a 
cause or a potential risk factor for its occurrence. There has been long-standing interest 
in investigating this possible association. However, the evidence for such a relationship 
is far from conclusive. The purpose of this study was to investigate the relationship 
between Toxoplasma seropostivity and cryptogenic epilepsy in children.  
2.3. Libya as a case study 
Libya is a developing country, where the environmental conditions and lack of 
awareness about toxoplasmosis' risks, are favourable for the transmission of this 
parasite. In addition, Libya has a National Epileptic Centre caring for many children with 
epilepsy of unknown origin and can provide a good resource for patients’ enrolment in 
this study. This is also the first study to be conducted in Libya determining the 
prevalence of toxoplasmosis amongst both non-epileptic and epileptic children.  
The data collected from this study will be useful to determine the association between 
epilepsy of unknown origin and the presence of anti-Toxoplasma antibody.  Its potential 
role in pathogenesis of epilepsy will be assessed. Epidemiologic data can be used for the 
design of measures for the prevention of this disease. 
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2.4.  Human Toxoplasmosis 
2.4.1. Epidemiology  
2.4.1.1. Global prevalence of toxoplasmosis  
The infection has a worldwide distribution. One-third of the world’s population has 
been exposed to this parasite (Dubey and Beatie, 1988)(Verma & Khanna 2013). The 
prevalence in humans varied significantly from region to region depending 
socioeconomic parameters, population habits and cultural factors (Boughattas et al. 
2010). Epidemiological studies recording prevalence of Toxoplasma gondii infection 
around the world indicate considerable variation between countries (Figure 1). It is 
highly prevalent (> 60%) in South America and tropical region of Africa. Moderate 
prevalence (30 to 50%) have been found in countries of Central and Southern Europe 
and low prevalence (10 to 30%) have been observed in North America, South East Asia, 
Northern Europe and in Sahel African countries (Robert-Gangneux & Dardé 2012) 
(Pappas et al. 2009a). 
Some Serological research  around the word showed that seroprevelance of Toxoplasma 
in several Latin-American countries including Brazil, Cuba, Jamaica, and Venezuela 
was even higher, with a  range from 51–72% (Tenter et al., 2000). In Brazil, a higher 
seropositivity was found among the poor socio-economic groups. In different regions of 
Brazil, the seropositive rate varied between 37% and 91% (Rodrigues et al. 2015) 
Seroprevalence is high in some European countries, particularly France. It is up to 54% 
in southern European countries (Fromont et al. 2009) and  decreases to 5–10% in 
northern, Sweden and Norway (Evengard et al., 2001). Prevalence in USA is 15.8% in 
the age group 12-49 year-old  (Shin et al. 2009). However, over the past four decades 
age-specific prevalence has been decreasing in Europe (Welton, 2005). In France, 
serological surveys showed a decrease in T. gondii prevalence among pregnant women 
from 80% in 1960 to 44% in 2003 (Villena et al. 2010). The same result was seen in 
other countries. A national survey found a decrease in T. gondii prevalence in US-born 
persons aged 12 to 49 years, from 14.1% in 1988 to 9% in 2004 (Jones et al. 2007). 
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In most Asian countries the seroprevalence of Toxoplasma gondii infection is still low, 
12.3% in China (Xiao et al. 2010),12.9% in Korea (Shin et al. 2009). But recent studies 
from Malaysia and India showed high seropositivity rates. Seroprevalence in Malays 
was 55.7 % (Nissapatorn et al., 2003), while it was 45%  in India  (Singh and Pandit, 
2004). The seroprevalence in human immune-deficiency virus (HIV)-positive patients 
was 10.2% in Taiwan (Hung et al., 2005) and 39.3% in Iran (Daryani et al. 2014). 
In African countries, numerous studies were performed in the early 1990s´. 
Seroprevalence was heterogeneous: Nigeria 20.8 %, Mali 21 %, Benin 3.6 %, Gabon 
71.2 %, Madagascar 83.5 % and Senegal 40.2 % (Pappas et al. 2009a).  
In Africa, toxoplasma seropositivity is considered to be a potential marker of HIV 
infection, due to the association between toxoplasma encephalitis and AIDS. African 
immigrants to the UK had a ten-fold higher incidence of symptomatic toxoplasma 
retino-choroiditis compared to white people born in Britain (Gilbert et al., 1999).  
 
Figure 1: Prevalence of human toxoplassmosis. 
 
Global status of Toxoplasma gondii seroprevalence. Dark red equals prevalence above 60%, 
light red equals 40–60%, yellow 20–40%, blue 10–20% and green equals prevalence <10%. 
White equals absence of data (Pappas et al. 2009b). 
  
 
13 
Figure 2:  Increasing Toxoplasma seropositivity with age. 
 
Rate of Toxoplasma gondii infection in various countries, showing increase of the Toxoplasma 
seropositivity with ages (Dubey and Beatie, 1988). 
 
2.4.1.2. Global prevalence of toxoplasmosis in children 
Information related to T. gondii infection among schoolchildren remains largely 
unknown to date. Due to the potentially serious implications of T. gondii infection on 
the foetus the majority of surveys focuses on childbearing age women, 
immunocompetent adults, and HIV/AIDS patients. The seroprevalence in Iran, 
Indonesia, Slovak, and Brazil was high, ranged from 20.9% to 68.4% (Souza et al. 
1987)(Fan et al. 2012). In developed countries, the prevalence of T. gondii infection 
among primary schoolchildren (PSC) was low, with a range of 0.0% to 11.0% in Japan 
and in  Ireland (Fan et al. 2012) (Taylor et al. 1997). Taylor et al. found seroprevalence 
of 12.8% in Irish children aged 4-18 years, with no difference between the sexes. 
Prevalence increased with age and was higher in countryside than towns, 16.6% and 
10.2% respectively  (Taylor et al. 1997). 
yr. 
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In Africa, the majority of surveys have been carried out on adults, women of 
reproductive age and on HIV/AIDS patients (Hammond-Aryee K, Esser M 2014). 
However, studies concerning the seroprevalence of T. gondii in children are limited; few 
studies have been performed in some countries. The seroprevalence of T. gondii 
infection among primary school children was 24%  in Nigeria (Gyang et al. 2015), 
37.5% in Somalia (Ahmed et al. 1988) and 52.1% in Madagascar (Dromigny et al. 
1996). The overall seroprevalence of T. gondii infection ranged from 21.49% to 63.1% 
in Democratic Republic of São Tomé and Príncipe (DRSTP) and West Africa (Fan et al. 
2012)(Fan et al. 2006), while in the Republic of the Marshall Islands it was found to be 
54.8% (Fu et al. 2014). 
In Asian countries prevalence was lower.  T. gondii infection among children aged 6-11 
years was 16.0-15.3% (Xin et al. 2015)(Meng et al. 2014). In Iran was 10% (Ali et al. 
2007). In Indonesia prevalence at 0-9 years in both genders was less than 10%, but in 
those at ages over 10 years there were more than 50%, suggesting an extremely high 
transmission rate (Konishi et al. 2000). In Bahrain, seroprevelance of toxoplasmosis 
was 9.3% (Tabbara & Saleh 2005) . 
In Latin American, a high seroprevalence of toxoplasmosis (55%) was found in children 
aged 13–17 yr. in Chile (Munoz-Zanzi et al. 2016). In Panama, seroprevalence has been 
reported to be 13% by age of 6 years (Frenkel et al. 1995). In Brazil, prevalence rates 
ranged from 17.5% (Dattoli et al. 2011) to 46.4% (Lopes et al. 2008). Seroprevalence 
according to age was: 2 to 9 years: 40.0%; 10-19 yr.: 60.4% (Rey & Ramalho 1999).  
In 1999, the prevalence of Toxoplasma gondii infection in Guatemalan children aged 
from 2 months to 2 years was 12.4%. In 2003, antibody prevalence increased to 43% at 
the age of five years (Jones et al. 2005). 
The discrepancy in seroprevalence in different countries could be attributable to 
different ethnicity, traditional culture, as well as food habits (Jones et al. 2009)(Cenci-
Goga et al. 2011).  
2.4.1.3. Prevalence of toxoplasmosis in North Africa and Middle East 
In North Africa, there is an average seroprevalence rate of 58%, with a progressive rise 
from 24% at 10 years of age to 70% at 30 years of age (Bouratbine et al. 2001). Recent 
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review by Pappas et al. summarized prevalence rates in neighbouring countries Egypt  
(57.9 %) and Tunisia (58.4 %) (Pappas et al. 2009a). Whilst in Morocco is 50.6 % 
(Hussein et al. 2001). 
 
Figure 3: Prevalence of toxoplasmosis in South Europe, North Africa and Middle 
East.  
 
Data from Pappas et al. 2009. 
 
2.4.1.4. Prevalence of toxoplasmosis in Libya 
In spite of the fact that toxoplasmosis is one of the most diseases distributed worldwide. 
Very little amount of literature has been published on seroprevalence and the 
epidemiology of the disease in the Libya. No epidemiological analysis was done at 
national level.  
Some studies have been conducted to determine the prevalence of T. gondii among 
pregnant women, carried out in some main cities such as Tripoli and Benghazi. 
However, like most developing countries, there is no national programme for screening 
pregnant women for toxoplasmosis in Libya. The first report in Benghazi was done by 
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Legnain and Prawecka (1983), who found seropositivity in 45.8% of pregnant women 
(Legnain M. M. and Prawecka M 1983). Seroprevalence of toxoplasmosis among 
pregnant women in Benghazi oscillated from 44.8 %  to 50% (Mousa et al. 2011) 
(Kassem & Morsy 1991) (Magrhi S et al. 2003). In the area of Tripoli, seroprevalence 
was 43,4% in adult females (Khadre & El Nageh 1987). In Misurata, 26,7% were 
positive in first trimester of pregnancy (Ramadan Sariti et al. 2015). In the Sebha region 
prevalence in pregnant women was 36,8% (El-Sayed & Almannoni 2016). The  overall 
incidence rates of T. gondii among pregnant and non-pregnant women from Ben Jawad 
were 37.16% and 35.5% respectively (Boshapor & Kassem 2015). Setta found low 
prevalence (18,6%) in non-pregnant women in Tripoli in 2006-2007 (Setta AM 
2008).Prevalence in women with spontaneous abortion was 45% in Tripoli in 2002-
2007 (Gashout et al. 2008), and decreased to 38,5% in 2010 (Gashout et al. 2016).  
Sero-prevalence of toxoplasmosis among Libyan psychiatric patients in Tripoli was 
61.7%. It was higher than in non-psychiatric controls, suggesting some pathogenic 
relation between toxoplasmosis and psychiatric diseases (Elsaid MM, Dia Eddin EE 
2014).  The main reasons for this high prevalence rate of toxoplasmosis in Libya is yet 
unclear as no adequate studies regarding transmission modes were available. 
 
Figure 4:  Prevalence of toxoplasmosis in women and pregnant women in Libya. 
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Information concerning T. gondii infection among schoolchildren is scant. Only one old 
published study investigated about the prevalence of Toxoplasma gondii infection in 
schoolchildren. In the area of Tripoli, seroprevalence was 43.7% in 1980 schoolchildren 
of 7–18 years of age (Khadre & El Nageh 1987). 
2.4.2. Transmission  
The only known definitive hosts for Toxoplasma gondii are members of family Felidae 
(domestic cats and their relatives). Intermediate hosts in nature (including birds and 
rodents) become infected after ingesting soil, water or plant material contaminated with 
Toxoplasma gondii oocysts (Jones et al. 2003) 
2.4.2.1. Pathways for Toxoplasma gondii infection transmission to humans 
Epidemiological surveys are the most useful way for assessing the relative importance 
of different sources of T. gondii infection in humans (Zuber and Jacquier, 1995). 
Consumption of raw meat (undercooked meat), drinking unboiled milk and and 
untreated water, contact while cleaning cat litter and soil contact has been shown to be 
an important risk factor in several studies (Sousa et al., 1988). Transplacental 
transmission from mother to foetus by tachyzoites, can cause severe neurological and 
ophthalmological sequels (Carruthers & Suzuki 2007). 
The importance of these modes of transmission may vary in different populations. 
Toxoplasma gondii has been identified in saliva, sputum, within mucosa of bladder and 
intestine and in the kidneys of infected humans. Contaminated human urine and faeces 
may be theoretically a source of infection, but transmission by this source has never 
been proved (Remington and Desmonts, 1983). Less commonly, toxoplasmosis has 
been transmitted by transplantation of an infected organ or thorough contaminated 
blood transfusion (Hill & Dubey 2002). Laboratory workers who handle infected 
animals or needles are at great risk. A total of 47 laboratory-acquired cases have been 
reported, 81% of them were symptomatic (Herwaldt, 2001). Transmission by sexual 
activity including kissing is probably rare and epidemiologically unimportant (Zuber & 
Jacquier 1995).  
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2.4.3. Biology of Toxoplasma gondii 
Toxoplasma. gondii is an obligate intracellular parasite. It has a complex life cycle 
consisting of sexual and asexual cycles (Figure 5) and different stages  (Dubey and 
Beatie, 1988) (Robert-Gangneux & Dardé 2012) (Tenter et al. 2000). The sexual cycle 
takes place only in primary host family Felidae, including domestic and feral cats. The 
asexual cycle takes place in a wide variety of intermediate hosts, including humans. 
2.4.3.1. Sexual cycle   
It’s an entero-epithelial cycle. It takes about 3-10 days and occurs only in the gut of the 
definitive hosts felids.  
Oocysts are eliminated by cat feces. Oocysts undergo sporulation in the soil, developing 
infective sporozoites. Each oocyst develops two oval sporocyst. Four sporozoites 
differentiate and grow inside each sporocyst. Oocyst become infective within 5 days 
depending on environmental conditions (Dubey and Beatie, 1988). 
 
Figure 5: Life cycle of Toxoplasma gondii. 
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Figure 6: Oocysts (Dubey et al, 1998). 
 
 
When cats ingest oocysts shed from other cats, sporozoites are liberated in gut lumen.  
Sporozoites where they differentiate into their rapidly multiplying form (tachyzoite). 
Tachyzoites invade epithelial cells and inside the enterocyte, the parasite undergoes 
several rounds of division. Intracellular divisions generate new tachyzoites and micro-
(male) and macro-(female) gametocytes. Fertilized gametocytes form a zygote or oocyst 
that is shed into the environment with the cat faeces.  
2.4.3.2. Asexual cycle 
Following ingestion of the oocyst by intermediate hosts (human and animals), extra-
intestinal cycle of infection develops. The sporozoite differentiates into the rapidly 
multiplying form tachyzoite. Tachyzoites are distributed via the blood stream thus 
establishing the acute infection parasitemia (acute stage). These tachyzoites invade neural and 
muscle cells and other tissues. Inside the cells tachyzoites are surrounded by a 
membrane (parasitophorous vacuole) and multiply as rosettes. Finally, the cell wall is 
Image from Dubey , Lindsay and Speer, 
Clin Microb Reviews, 1998. 
A.  Unsporulated oocyst. 
B.  Sporulated oocyst showing two 
sporocysts. Right sporocyst 
shows four spozoites developing 
inside (arrows). 
C. Sporulated oocyst with four 
sporozoites inside each 
sporocyst. 
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broken and new tachyzoites are liberated. Some tachyzoites transform into a slowly 
dividing form known as bradyzoites and begin to multiply forming tissue cysts (chronic 
stage).  
Latent bradyzoite tissue cysts are the terminal life-cycle stage in the intermediate host. 
They may persist for the life of the host or ruptured and released bradyzoites become 
active tachyzoites and start to proliferate again (Dubey and Beatie, 1988, Remington 
and Desmonts, 1983).  
Meat and other tissues of infected animals include tissue cysts. After ingestion of tissue 
cysts, bradyzoites are liberated in the digestive tract of definitive or intermediate hosts, 
transform into tachyzoites and begin tissue invasion. 
 
Figure 7: Intracellular tachyzoites. 
 
Sarah Myers, 2014. 1: HeLa cell filled by tachyzoites. 2: tachyzoites actively emerge through 
cell wall. 
2.4.3.3. Toxoplasma morphology 
Tachyzoites: asexual proliferative forms involved in cell invasion. It has a semilunar 
shape, measures 3 to 7 microns (Figures 7 and 8). They are obligate intracellular 
microorganisms, but they can survive outside the cells in various body fluids for periods 
of hours or days. They convert into bradyzoites inside cells (Montoya and Liesenfeld, 
2004, Dubey and Beatie, 1988). They do not survive digestive activity of the stomach 
and are not infectious by ingestion. However, they can cause trans-placental infection. 
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Tissue cysts: tissue cysts size ranges from 10-200 microns in diameter.  Found in the 
brain,skeletal and cardiac muscles. They are rounded in brain and elliptic in muscle 
cells (Montoya and Liesenfeld, 2004). Inside they include bradyzoites, similar to 
tachyzoites but smaller and divide more slowly. They are more resistant to digestive 
enzymes and, just as the oocysts are infectious for the animals that ingest them. They 
survive in normal cooling temperatures, but can be destroyed by freezing, thawing and 
usual cooking temperatures. 
Oocysts: they have ovoid shape, measure 10 to 12 microns in diameter (Figure 6). They 
possess a thick wall that makes them resistant to most environmental factors. They can 
be destroyed at cooking temperatures.  They are their immature form, the center of the 
cyst appears with two sporocysts and later four sporozoites can be identified in each 
sporocyst. This form is the one that participates in the dissemination of the feline 
parasite to another animal and fecal-oral route. The number of oocysts eliminated in the 
fecal matter can reach 10 million daily for periods of 20 days. 
 
Figure 8: Tachyzoites. 
 
Toxoplasma gondii tachizoites in mouse peritoneal fluid. CDC. 
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Figure 9: Brain tissue cysts of Toxoplasma gondii. 
 
Brain tissue cysts. JWM. Gold.. 1986. Public Healh Image Library (PHIL)-CDC. 
 
Figure 10: Bradizoites. 
 
Bradizoites inside tissue cyst in brain of infected mouse. David Ferguson. EurekaAlert.org. 
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Figure 11: Tissue cyst in myocardial muscle. 
 
Histopathology of active toxoplasmosis of myocardium. EP. Ewing, 1984. PHIL-CDC. 
2.5. Diagnostic of toxoplasmosis 
Diagnosis of toxoplasmosis is made indirectly with serological methods and directly by 
detection of the parasite or its DNA (Montoya & Liesenfeld 2004). 
2.5.1. Serology  
IgG antibodies: The most commonly used tests, usually appear within 1–2 weeks, peak 
within 1–2 months than then decline and usually persist for life.  It measurement of IgG 
antibody are the DT, the ELISA, the IFA, and the modified direct agglutination test 
(Montoya 2002). IgG titers over 8 IU/mL are generally accepted as positive, but there 
are differences between the results obtained by different manufacturers of tests (Villard 
et al. 2016). High titers are related to recent infection, symptomatic infection (Vidal et 
al. 2011) and reinfection or reactivation (Dzitko et al. 2006). Sabin-Feldman dye test 
and inmunoblot techniques (Sroka et al. 2016) are the reference methods. 
Avidity of IgG antibodies:  It is the better test for confirm recent infection. Method 
described by Hedman et al. is based on the distinct strength of the binding between 
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antigen and antibody in infection acute and chronic (Hedman et al. 1989). IgG with low 
avidity predominates in the early stages, whereas in chronic infection it occurs the 
opposite situation. In fact, there are IgGs of high and low avidity always; what varies is 
the relative proportion each type. The presence of highly avid IgG antibodies in excess 
of 30% excludes acute infection. 
IgM antibodies: An IgM test is still used to determine recent infection. IgM antibodies 
remains positive for over 2 years (del Castillo 2005). Recent infection is better 
diagnosed by detecting low avidity IgG. Confirmatory testing should always be 
performed. Commonly measured by double-sandwich or capture IgM-ELISA kits, the 
IFA test and the immunosorbent agglutination assay (Montoya 2002).   
IgA and IgE antibodies: Are detected in sera of acutely infected adults and congenitally 
infected infants by use of ELISA or ISAGA (Montoya 2002).  
2.5.2. Polymerase Chain Reaction 
It has successfully been used to diagnose congenital, ocular, and cerebral and 
disseminated toxoplasmosis by detect T. gondii DNA in body fluids and tissues 
(Montoya 2002). At the moment, the PCR techniques allow to avoid the culture in the 
majority of the situations. In the CSF sensitivities are obtained between 40 and 50%. 
2.5.3. Isolation of T. Gondii 
The diagnosis of certainty can be established by cell culture. The culture techniques in 
the experimental animal should be limited to situations of special diagnostic difficulty. 
Intraperitoneal inoculation to mouse is the reference method. 
2.5.4. Histological diagnosis  
Infection is confirmed by demostration of tachyzoites or tissue cysts in tissue sections or 
smear of body fluid (e.g., CSF amniotic fluid and blood in patients with AIDS). Direct 
immunofluorescence (Matossian et al. 1977) and immunohistochemical techniques are 
the preferred methods for direct identification of Toplasma gondii in tissue samples. 
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2.6. Toxoplasmosis and neurological outcomes 
Infection with the toxoplasma parasite can cause several neurologic syndromes:  
2.6.1. Congenital toxoplasmosis and CNS 
Women infected with Toxoplasma before conception, with rare exceptions, do not 
transmit the infection to their foetuses. Congenital infection occurs when a woman is 
infected acutely or has a reactivation during pregnancy (Jones et al., 2003). It is not 
transmitted in subsequent pregnancies. In Europe it estimated to occur in between 1-
10/10000 live births (Antoniou et al., 2004). The incidence and severity of congenital 
toxoplasmosis depends on the gestational age at which maternal infection occurs. It is 
more frequent as the pregnancy progresses, ranging from less than 2% at gestational 
week 4 to more than 80% at 36
 
weeks gestation (Montoya and Liesenfeld, 2004). 
However, the consequences become less severe as the gestation progresses. An 
estimated one half of untreated maternal infections are transmitted to the foetus. (Dunn 
et al. 1999). If untreated, congenital toxoplasmosis can be associated with severe and 
even fatal disease (Jones et al., 2003; Paul et al., 2001). 
2.6.1.1. Asymptomatic congenital toxoplasmosis 
Most infants infected in utero are born with no obvious signs of toxoplasmosis on 
routine examination, includes babies with positive serology that persists longer than 12 
months. They may develop learning and visual disabilities later in life. 
2.6.1.2. Symptomatic congenital toxoplasmosis 
A small minority of babies will have symptomatic congenital toxoplasmosis. The 
classical triad of signs suggestive of congenital toxoplasmosis include chorioretinitis, 
intracranial calcifications (Figure 12) and hydrocephalus. Other clinical manifestations 
also occur, such as hepatosplenomegaly, pneumonia, thrombocytopenia, 
lymphadenopathy or myocarditis (Table 1).  
Diagnosis can be confirmed serologically by IgM positive, with an IgG titre 
significantly greater than mothers (Holliman, 2003) or by immunoblotting of IgG 
antibodies (Chumpitazi et al. 1995). Toxoplasma gondii DNA can be detected in 
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amniotic fluid, placenta, blood, CSF or urine using molecular methods such as 
PCR (Meenken et al., 1995; Zhang et al., 2002). 
 
Table 1: Clinical manifestations of congenital toxoplasmosis. 
Signs and symptoms of congenital toxoplasmosis in infants and children* 
Intracranial calcifications† 
Hydrocephalus† 
Chorioretinitis† 
Abnormal spinal fluid 
Microcephaly 
Spasticity and palsies 
Convulsions 
Visual impairment 
Deafness 
Learning disabilities 
Mental retardation 
Hepatomegaly 
Splenomegaly 
Anaemia 
Thrombocytopenia 
Jaundice 
Lymphadenopathy 
Maculopapular rash 
Fever 
Growth retardation 
 
*Most neonates with congenital toxoplasmosis are asymptomatic on routine new-born 
examination. †Signs of the classic triad suggesting the presence of congenital toxoplasmosis 
(Jones et al., 2003).  
 
Figure 12: Hydrocephalus and brain calcifications in congenital toxoplasmosis. 
                  
Dr. Ahmed Abdel Khalek 
2011. 
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2.6.2. Retinal toxoplasmosis 
Progressive and recurrent focal necrotising chorioretinintis is the hallmark of congenital 
infection or infection after birth (Figure12). In congenital infection, patients are often 
asymptomatic at birth. Clinical symptoms are most commonly manifested during 
infancy and adolescence (Roizen et al., 2006). It is seen in 75-80% of cases and 85% are 
bilateral (Wu, 2007). It was reported to be a rare feature of acquired infection, with only 
1-3% of patients in old case-series (Gilbert and Stanford, 2000), but recent studies 
shows increased importance of acquired infection as aetiology of retinal toxoplasmosis 
(Arantes et al. 2015) (Balasundaram et al. 2010).  
Cysts deposited on the retina cause focal necrotizing retinitis; those deposited in the 
optic nerve cause optic neuritis or papules called Jensen disease (Wu, 2007). Further 
abnormal ocular features include  optic nerve atrophy, strabismus, microophthalmus, 
cataracts and iris abnormalities (Meenken et al., 1995). 
 
 
Figure 13: Retinal toxoplasmosis. 
      
Central retina scar from toxoplasmosis 
chorioretinitis. 
© International Centre for Eye 
Health, 1998. 
London School of Hygiene & Tropical 
Medicine. 
Some rights reserved. 
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2.6.3. Brain toxoplasmosis in inmmunodefiency 
In immunocompromised patients the central nervous system (CNS) is the most 
commonly affected site and approximately 2.5% of AIDS patients have been diagnosed 
with cerebral toxoplasmosis. Immunosuppression may be caused by AIDS or therapies 
for malignancies, transplants, or lymphoproliferative disorders. Toxoplasmosis can be 
due to either a newly acquired infection or as result of reactivation of latent 
Toxoplasmosis (Montoya and Liesenfeld, 2004). Reactivation most often involves the 
central nervous system, and symptoms can include meningoencephalitis or symptoms of 
a mass lesion. CNS toxoplasmosis commonly presents with; focal neurological signs, 
motor weakness and speech disturbances (Montoya and Liesenfeld, 2004). 
Chorioretinitis and pneumonitis are more frequent in recipients of bone-marrow 
transplants. Moreover, multi-organ failure and septic shock may occur (Montoya and 
Liesenfeld, 2004). Skin involvement is rare (Leyva and Santa Cruz, 1986).  
 
 
Figure 14: Brain toxoplasmosis in HIV infected girl with severe 
inmmunodeficiency. 
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2.6.4. Brain toxoplasmosis in immunocompetent host 
The severity of Toxoplasma infections is correlated with the immune status of the 
infected subject. Toxoplasmosis in immunocompetent adolescents or adults is generally 
an asymptomatic infection in 70% to 90% of cases.  
About 10 to 20% of patients present mild symptoms, as painless lymphadenopathy, 
fever, fatigue and malaise. All of which usually resolve within one week to three 
months without specific treatment (O'Connell et al., 1993). In rare cases ocular infection 
with visual loss can occur (Ryning and Mills, 1979).  
A generalized transient non-pruritic maculopapular rash may occur, most prominent on 
the trunk and proximal extremities. Rash may be accompanied by fever, malaise, 
myalgia and sore throat (Ryning and Mills, 1979; O'Connell et al., 1993). Other clinical 
findings are very infrequent. Pericarditis, pneumonitis, nephritis, hepatitis, polyneuritis, 
haemolytic anaemia are described (Sano et al., 2000)(Cook et al 2003).  
Encephalitis occurs exceptionally in immunocompetent humans (Lescop et al. 1995; 
Hoti et al. 2016; Akturk et al. 2017). Initial neurological symptoms are equivalent to 
those observed in HIV patients, headache, vomits, focal seizures, psychiatric symptoms 
and somnolence (Barbic 2014; Alapatt et al. 2009; Li et al. 2014). Post infectious 
encephalomyelitis was also described after acute Toxoplasma gondii infection (Aksoy et 
al. 2013). 
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2.7. Epilepsy 
2.7.1.  Introduction 
Epilepsy is one of the world’s most prevalent non-communicable diseases that affect 
nearly 50 million patients worldwide (Ngoungou et al. 2015). It is one of the most 
common serious neurologic diseases, associated with social stigma and significant 
economic costs (Benamer & Grosset 2009).  
The prevalence of epilepsy is relatively high in many different parts of the world, 
between 2.3-44/1000 in all age groups. Among the paediatric age group, the prevalence 
of epilepsy is 18.5 (0.8-49) /1000 (Aydin et al. 2002). 
The epilepsies are an important cause of neurological morbidity in children. Factors that 
are known to increase risk of the epilepsies in children account for only 25% to 45% of 
cases. Aetiologies include congenital malformations of the central nervous system 
(CNS), CNS infections, head trauma, some inherited metabolic diseases and genetic 
factors (Cowan 2002).   
The International League Against Epilepsy (ILAE) defined Epilepsy as a disorder of the 
brain characterized by an enduring predisposition to generate epileptic seizures and by 
neurobiological, cognitive, psychological and social consequences (Fisher et al. 2005).  
It is classified into idiopathic for which there is no apparent cause, cryptogenic if an 
aetiology is unknown, but an underlying brain disease is suspected (Yazar et al. 2003) 
and secondary epilepsy if there is a known cause such as congenital abnormalities, 
trauma or hypoxia (Akyol et al. 2007). Cryptogenic epilepsies comprises about 20% of 
all epilepsy syndromes (Mrcp et al. 1992) 
Although the rates of idiopathic ⁄ cryptogenic epilepsy (60–70%) and symptomatic 
epilepsy (30–40%) are similar in developing and developed countries, the causes of 
symptomatic epilepsy are different. In the developing countries infections of the central 
nervous system, whether acute or chronic–recurrent, are the most important cause of 
seizures and acquired epilepsy (Singhi 2011). Cryptogenic epilepsies comprise about 
20% of all epileptic syndromes. 
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2.7.2. Epidemiology 
2.7.2.1. Global prevalence of epilepsy 
The World Health Organization estimates that epilepsy affecting over 50 million people, 
of whom 80% live in poor countries (http://www.who.int/healthinfo/statistics) (WHO 
2001) (Wagner & Newton 2009). In 75% of cases, epilepsy begins in childhood (Pal et 
al. 2000) (Jallon 1997) (Senanayake & Roman 1993). The average annual rate of new 
cases (incidence) of epilepsy is approximately 5-7 cases per 10,000 children, from birth 
to age 15 years (Cowan 2002). Its burden is higher in developing countries than 
industrialized countries, particularly in Africa and Latin America (Nicoletti et al. 2002). 
In Africa, the median prevalence is 5-74 ⁄ 1000 (Preux & Druet-Cabanac 2005), in 
South America the range is 6-43 ⁄ 1000 (Burneo et al. 2005), and in Asia it is 2-14 ⁄ 
1000 (Mac et al. 2007) compared to 3-8 ⁄ 1000 in Europe (Forsgren et al. 2005) 
(Montano et al. 2005). The great variability of prevalence rates is a reflection of 
different socioeconomic and sanitary situations and of individual study designs and 
methodologies (Eriksson & Koivikko 1997).      
2.7.2.2. The epidemiology of the epilepsies in children 
Epilepsies are an important cause of neurological morbidity in children. The incidence 
of epilepsy is approximately 5-7 cases per 10,000 children from birth to age 15 years, 
and in any given year, about 5 of every 1,000 children will have epilepsy.  
Some epileptic syndromes are unique to children, including infantile spasms, Lennox-
Gastaut syndrome and absence seizures. Febrile seizures and neonatal seizures are 
relatively common types and markers of risk of later epilepsy.  
The aetiology of most cases of the epilepsies remains obscure. However, there are some 
conditions that are known to increase risk of epilepsy in children. They include 
congenital malformations of the central nervous system, severe head trauma, CNS 
infections, certain inherited metabolic conditions and genetic factors. However, these 
account for only 25% to 45% of cases (Cowan 2002). 
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2.7.2.3. Prevalence of epilepsy in Arabic countries 
Epidemiologic data are lacking from the majority of Arabic countries. The estimated 
median prevalence of epilepsy in Arab countries is 2.3/1,000 (varying from 0.9-
6.5/1,000). This is just within the range found in Europe and Asia (Forsgren et al. 2005) 
(Mac et al. 2007). The prevalence rate is approximately 2-fold higher in children and 
young adults, compared to middle age and in male more than female. All the studies 
from the Arab states found generalized seizures to be more common than partial 
seizures; idiopathic epilepsy represents 73.5-82.6% of cases (Benamer & Grosset 2009). 
2.7.2.4. Prevalence of epilepsy in Libya 
Epidemiologic studies and general profile of epilepsy in Libya were lacking in 
particular data concerning aetiology of epileptic syndromes and their distribution across 
ages, gender, geographic distribution, costs and handicaps. Therefore, accurate epilepsy 
studies with well-defined epidemiological methods are necessary to verify the existing 
data and to determine the dimensions of the impact and burden of epilepsy in Libya.  
However, one study reported higher prevalence in males but similar rate in middle-age 
and older individual. Idiopathic epilepsy represented 82.6% while symptomatic epilepsy 
was considered 18% (Sridharan et al. 1985). 
2.7.3. Epilepsy and toxoplasmosis 
Toxoplasmosis has recently been associated with some neurological disorders, 
particularly schizophrenia (Torrey & Yolken 2003) (Emelia et al. 2012) (Esshili et al. 
2016),
  
depression and bipolar disorder (Benazzi 2007) (Prandota 2009) (Duffy et al. 
2015).
  
However, evidence for causal relationships remains limited. 
Over the past decade there has been an increasing interest in the possibility of an 
association between Toxoplasma gondii infection and epilepsy of unknown 
origin. Some studies focused on toxoplasmosis as a possible cause of cryptogenic 
epilepsy. Others looked into a relationship between toxoplasmosis and seizures of all 
types. In a search for comparative studies on the relationship between toxoplasmosis 
and cryptogenic epilepsy published until to date, we identified a total number of thirteen 
case-control studies that were carried out in 6 different countries or regions: USA, 
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Egypt, Iran, Turkey, Israel and some countries of Sub-Saharan Africa (Figure 16). 
Resumed information is available in tables 2 and 3. 
2.7.3.1. Controlled studies 
Two studies have been carried out in Turkey. Yazar et al. (2003) reported that the 
percentage of seropositivity to IgG against T. gondii was higher in 50 patients 
diagnosed of cryptogenic epilepsy (52%) than in 50  patients with symptomatic epilepsy 
and 50 healthy controls (22% and 18% respectively) (Yazar et al. 2003). This result is 
contrary to that reported by Akiol et al. (2007), who didn’t find differences in 
prevalence of T. gondii infection between 100 patients with cryptogenic epilepsy and 50 
healthy controls (Akyol et al. 2007).  
Stommel and his colleagues (New Hampshire, U.S.A., 2001) compared 22 adults with 
cryptogenic epilepsy and 23 healthy adults as controls. They used qualitative ELISA for 
detecting IgG anti T. gondii and assessed optic density readings as a surrogate marker of 
IgG titers. They found that 75% of subjects with cryptogenic epilepsy, had antibody 
titers higher than median for controls. Authors concluded that increased anti-
Toxoplasma antibody titers indicate that chronic T. gondii infection may be a cause of 
cryptogenic epilepsy (Stommel et al., 2001). 
igure 15: Countries with studies about Toxoplasma gondii and epilepsy. 
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Table 2: Description of data extracted from the previous studies investigating an 
association between toxoplasmosis and epilepsy. 
Authors Region Type of study  OR (95% CI) P-value 
Potasman et al. 1995 Israel Hospital based  2.36 (0.91-6.08) NS: 0.11 
Stommel et al. 2001 USA Hospital based 2.62 (0.72-9.54)  NS:0.075 
Yazar et al. 2003 Turkey Hospital based 5.35 (2.15-13.30)  <0.001 
Akyol et al. 2007 Turkey Hospital based 1.80 (0.80-4.05) NS: 0.2 
Zibaei et al. 2011 Iran Hospital based 3.33 (1.03-10.78)  <0.05 
Allahdin et al.2015 Iran  Hospital based 0.30 (0.2-0.6) <0.001 
El-Tantawy et al 2013 Egypt Hospital based 2.01 (1.01-3.73) <0.05 
Eraky et al. 2016 Egypt Hospital based 6 (1.19-30.10) <0.05 
Kamuyu et al 2014 sub-Saharan 
Africa 
Community 1.28 (1.04-1.56) <0.05 
Ngugi et al 2013 sub-Saharan 
Africa 
Community 1.39 (1.05-1.84) <0.05 
 
There are three studies in Iran about the rate of Toxoplasma gondii infection in epileptic 
patients.  Zibaei et al. (2011) compared the rate of Toxoplasma infection in 85 epileptic 
patients with 85 healthy controls in west of Iran; they reported higher rate of the 
infection in epileptic patients (14.1 %) compared to the healthy controls (4.7 %) (Zibaei 
et al. 2011). In contrast, results of a study from south of Iran (Allahdin et al. 2015) 
indicated lower incidence of Toxoplasma infection in epileptic patients than in healthy 
controls (14.2 % versus 30.4 %). A more recent study by Babaie et al. (2017), estimated 
that the seroprevalence of Toxoplasma infection in Iranian epileptic patients (n=414), 
was not different from patients with non-epileptic neurologic disorders (n=150) and 
healthy controls (n=63); they didn’t find significant differences in antibody titers 
(Babaie, Sayyah, Gharagozli, et al. 2017).    
In Egypt, El-Tantawy et al. (2013) compared the frequency of anti-Toxoplasma 
seropositivity in 132 children diagnosed of cryptogenic epilepsy, aged 5 to 14 years, and 
60 age-matched controls. They found that prevalence of T. gondii infection in children 
with cryptogenic epilepsy was 60.6% and 43.3% in controls (p < 0.001) (Labeeb El-
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Tantawy et al. 2013). Similar findings were reported by Eraky et al. (2016), when they 
compared the rate of antibodies against Toxocara and Toxoplasma gondii among 40 
children with cryptogenic epilepsy, 30 with non-cryptogenic epilepsy and 20 healthy 
control children. Their results showed that the rate of anti-T. gondii IgG seropositivity 
was higher among children with cryptogenic epilepsy (20%) than among children with 
non-cryptogenic epilepsy (0%) and healthy controls (10%) (Eraky et al. 2016). 
 
Table 3: Summary of prevalence rates in previous studies investigating an 
association between toxoplasmosis and epilepsy. 
Author  Epileptics Controls  
   Age  Nº Toxo % Nº Toxo % p value 
Potasman (1987-91, Israel) 1–15 52 19.2% 109 9% NS 
Stommel (1997-99, USA) Adults 22 75% 23 56.5% NS  
Yazar (1999-2002, Turkey) 
- Cryptogenic 
- No cryptogenic 
 
Adults 
 
 
50 
50 
 
54% 
22% 
 
50 
 
18% 
 
<0.001 
Akyol (2003, Turkey) 11-64 100 31% 50 20% NS 
Zibaei (2010, Iran) 7-62 85 14.1% 85 4.7% <0.05 
Alladin (2015, Iran)  2-39 yr 141 14.2% 144 30.4% NS 
Babaie (2016, Iran) 
- Epileptics 
- Neurological deficit no epil. 
 
18-64 yr 
 
 
414 
 
 
35.3% 
 
 
63 
150 
 
38.1% 
34.7% 
 
NS 
El-Tantawy (2013, Egypt) 1-14 yr  132 60.6% 60 43.3% <0.05 
Eraky (2016, Egypt) 
- Cryptogenic epilepsy 
- Secundary epilepsy 
 
9m-18 yr 
 
 
40 
30 
 
20% 
0% 
 
20 
 
10% 
 
<0.05 
Naglaa Fathy (2016, Egypt) 
- Depression  
- Cryptogenic epilepsy 
- No cryptogenic epilepsy 
2-46 yr  
 
72 
40 
 
 
34.7% 
2.5% 
60 
118 
11.7% 
20.3% 
<0.05 
Ngugi (2007-11, SSA)  ≥18 yr 555 47.7% 692 44.4% <0.05 
 <18 yr 416 27.6% 599 20.5% NS 
Kamuyu (2014, SSA) 0- ≥50 986  39.1% 1313 35.4% <0.05 
Toxo %: Percentage of IgG anti-Toxoplasma gondii positive. SSA: sub-Saharan Africa 
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Ngugi et al. (2007), conducted large population-based cross-sectional and case-control 
studies to assess the prevalence and risk factors of active convulsive epilepsy in African 
patients. Study was performed across five centres in five sub-Saharan African countries 
(Kenya, South Africa, Ghana, Uganda and Tanzania). Anti-T. gondii seroprevalence in 
children (age <18 years) was not different between controls (25% of 599 tested) and 
epileptics (27.6% of 419 tested). But exposure to T. gondii in control adults (44.4% of 
692 tested) was slightly lower than in epileptic adults (47.7% of 555 tested; p<0.05) 
(Ngugi et al. 2013). Kamuyu et al. (2014) studied exposure to multiple parasites and its 
relation to epilepsy in a case-control study. Study subjects were recruited in the same 
centres previously used by Ngugi, at five sub-Saharan countries. Seroprevalence of 
toxoplasma gondii infection was slightly higher in epileptics than in controls (39,1 % of 
971 vs. 35.4 % of 1291) (Kamuyu et al. 2014).  
2.7.3.2. Systematic reviews and meta-analysis 
There are two meta-analysis in medical literature about the relationship between 
Toxoplasmosis and human epilepsy, made by Palmer (2007) and Ngoungou (2015). 
They found consistent higher rates of toxoplasmosis among epileptic patients than in 
control groups. The first meta-analysis was based on only three studies and found an 
Odds Ratio (OR) of 4.80 (95% CI 2.60-7.80) (Palmer 2007). Second meta-analysis 
based on six controlled studies found a lower OR of 2.25 (95% CI 1.15–3.93) 
(Ngoungou et al. 2015). Both authors concluded that there is a possible link between 
cryptogenic epilepsy and chronic toxoplasma infection.  
However, the relationship between epilepsy and Toxoplasmosis has not been fully 
demonstrated. Quet (2007) argued that evidence of association between epilepsy and 
toxoplasmosis has not been sufficiently investigated, and, to date, there is doubt about 
whether this implicates causality and draw definitive conclusions (Mac et al. 2007) 
(Quet et al. 2008).  
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Figure 16: Scatter plot of odds ratios for epidemiological correlation between 
toxoplasmosis and epilepsy.  
 
Ngoungou EB, Bhalla D, Nzoghe A, Dardé ML, Preux PM (2015) Toxoplasmosis and Epilepsy- 
Systematic Review and Meta-Analysis. PLOS Neglected Tropical Diseases 9(2): e0003525. 
https://doi.org/10.1371/journal.pntd.0003525 
 
2.7.3.3. Pathogenesis of neurological symptoms 
From the digestive tract, tachyzoites are distributed via the blood stream, establishing 
the acute infection parasitemia (acute stage). Finally, tachyzoites localize to muscle and 
CNS, where they differentiate in bradyzoites and multiply inside cells forming tissue 
cysts (chronic stage).  
Latent infection (bradyzoites) is thought to be asymptomatic, because it is controlled by 
the intact immune system (Frenkel 1988). When the immune system becomes 
suppressed, i.e. AIDS, bradyzoites are reactivating, converting into rapidly proliferating 
tachyzoites that may cause lethal encephalitis if untreated.  Alternatively, cyst rupture 
and formation of new cysts may be a constant process, even in immunocompetent 
individual (Feustel et al. 2012; Montoya & Liesenfeld 2004).  
2.7.3.4. Possible mechanisms for epileptogenesis in T. gondii CNS infection 
One can postulate how a dormant CNS infection such as T. gondii could cause epilepsy. 
Epileptic discharge may occur with a membrane defect leading to instability or 
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abnormalities of potassium, calcium channels or GABA inhibitory system (Palmer 
2007). 
In vitro infection of cultured CNS cells show the primary infection of T. gondii in 
astrocytes, microglia and neurons (Mammari et al. 2014). But there is clear tropism 
of T. gondii for neurons in which encysted parasites were exclusively found (Cabral 
et al. 2016). This is not due to selective invasion; there may be unknown properties 
of neurons that promote cyst development.  
In the mouse model, there is evidence of focal inflammation with disrupted tissue cysts 
(Sims & Hay 1995). Toxoplasma tissue cysts mature slowly and have been shown to 
eventually lyse in the immunocompetent host, producing microscopic scars (glial 
nodules) (Bertoli et al. 1995).  
Intermittent increase of anti-Toxoplasma IgG levels in some patients suggests that the 
bradyzoites may reactivate and subsequently produce an antibody response (Frenkel 
1988). Reactivation of the cysts could depolarize cells being exited or entered. When T. 
gondii has entered the cell, it is then able to hijack the host cell Ca
2+
-pump. Before T. 
gondii leaves the host cell, there is an increase in the intracellular Ca
2+
 concentration, 
which allows T. gondii to escape and is followed with lysis of the host cell. Cell lysis 
will also cause microglial formation (Frenkel & Escajadillo 1987). 
Toxoplasma encephalitis is characterized by many foci of enlarging necrosis and 
microglia nodules that calcify and lead to radiological changes and can  rise to epileptic 
discharges (Cook et al. 2000) (Dubey et al. 1998). The formation of scar tissue has been 
suggested to be one of the main theories for the cause of epilepsy (Prayson & Frater 
2002). 
Neurons infection by Toxoplasma gondii promote changes in regulation of 
neurotransmitters. Stibbs described changes in neurotransmitter concentration in the 
brains of chronically infected mice, with reduction in serotonin and norepinephrine, and 
an increase in total dopamine (Stibbs 1985). Other authors also found increased 
dopamine turnover in in chronically infected mice (Prandovszky et al. 2011) (Ihara et al. 
2016). It has been observed in vitro that dopamine is able to increase parasite 
proliferation (Strobl et al. 2012). Treatment of rats and mice with dopamine D1 an D2 
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receptor antagonists inhibit the establishment of behavioral changes after 
experimental T. gondii infection (Webster et al. 2006). 
T. gondii infection decreases the threshold of clonic seizures produced by infusion of 
pentylenetetrazole in mice. This increased susceptibility to seizures was confirmed in 
acute and chronic phases of T. gondii infection (Babaie et al. 2017). These authors 
demonstrated that increased seizure susceptibility was reversed with pre-treatment with 
dopamine inhibitors. Treatment of toxoplasmosis with trimethoprim/sulfamethoxazole 
definitively restored the susceptibility for seizures to the level of uninfected mice 
(Babaie et al. 2017). 
  
  
 
40 
 
 
 
 
 
 
  
HIPOTHESIS  
AND OBJECTIVES 
  
  
 
41 
3. HYPOTHESIS AND OBJECTIVES  
A link between acquired epilepsy and toxoplasmosis was suggested by some authors in 
recent years. But most studies checking this possible relation are small and some shows 
contradictory results. 
Cryptogenic epilepsy lacks of known aetiology, but it is suspected to be secondary. 
Patients with cryptogenic epilepsy have not known cause of epilepsy after considering 
his personal and familial antecedents, habitual neurological studies and clinical data. If 
Toxoplasma gondii infection can cause epilepsy, probably patients with epilepsy 
secondary to toxoplasmosis will be catalogued as cryptogenic epilepsy. It is less 
probable that patients with epilepsy secondary to toxoplasmosis will have other known 
cause of epilepsy or genetic epilepsies. 
3.1. Hypothesis 
We hypothesized that Toxoplasma gondii infection can cause epilepsy in children. If 
toxoplasmosis is related to development of epilepsy, children with suspected 
cryptogenic epilepsy in Libya will have a higher frequency of Toxoplasma gondii 
infection than non-epileptic children. Children with suspected cryptogenic epilepsy will 
also have a higher frequency of Toxoplasma gondii infection than epileptic children 
with known causes of epilepsy. 
3.2. Objectives 
3.2.1. Main objective 
The main objective of the present work is to determine if acquired Toxoplasma gondii 
infection is related to the development of cryptogenic epilepsy in Libyan children.  
To assess this question, we will determine: 
 If children with suspected cryptogenic epilepsy have higher frequency of 
Toxoplasma gondii infection than non-epileptic children. 
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 If children with suspected cryptogenic epilepsy have higher frequency of 
Toxoplasma gondii infection than children with symptomatic epilepsy. 
 If children with suspected cryptogenic epilepsy have higher anti-Toxoplasma gondii 
IgG titers than controls.  
3.2.2. Secondary objectives  
 To assess possible relations of toxoplasma gondii infection with seizure types and 
degree of control of epilepsy. 
 To estimate the prevelance of Toxoplasma gondii infection in children with 
epilepsy.  
 To estimate the prevelance of Toxoplasma gondii infection in non-epileptic children 
selected as controls.  
 To identify risk factors and possible routes of infection associated with Toxoplasma 
gondii infection and quantify their influence. 
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4. SIGNIFICANCE OF THE STUDY 
In Libya, there is not much evidence-based information on T. gondii infections among 
high-risk groups. Our data will not provide a complete picture of prevalence of T. 
gondii infections in the entire population of Libya; but this is a new area of research and 
may provide the basis for extended future studies. 
Toxoplasmosis is a preventable disease. Understanding the possible association between 
toxoplasmosis and epilepsy could be an important step in future effort to prevent 
epilepsy in low resource settings countries and subsequently reduce of the morbidity 
and financial expenditure for the treatment of patients. 
Identification of main transmission routes of the infection in Libyan children will be 
useful for planning optimal measures against infection. In the future, it may allow for 
the implementation of appropriate public health policies, through increased awareness 
and better control of toxoplasmosis. 
If possible links between Toxoplasma gondii infection and epilepsy are confirmed, 
appropriate strategies can be designed to include this knowledge in the treatment of 
patients. Diagnosis of toxoplasma infection can be included in the routine study of 
epileptic patients. The information available in the experimental models on the most 
effective drugs to deal with toxoplasmosis-related seizures, could be transferred to the 
clinical care of the patients. Finally the treatment of toxoplasmosis could be considered 
in those patients in whom this infection may play an etiological or aggravating role of 
their epilepsy. 
 
 
 
  
  
 
45 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
METHODS 
  
  
 
46 
5. METHODS 
5.1. Introduction to the study 
 
We have designed a controlled study for epileptic patients attending the National Center 
for the Treatment of Epilepsy in Tripoli, Libya. Controls were selected from a group of 
non-epileptic patients who attended the general paediatrics outpatient clinic at the 
Tripoli Medical Centre hospital during the same period. The total number of 
participants was 298. Blood samples were collected and tested for the presence of 
antibodies against Toxoplasma using an immunoenzymatic assay. Data on risk factors 
for T. gondii infection were obtained through personal interview and review of medical 
records. 
5.2. Study design 
A comparative hospital-based study was undertaking. The prevalence of anti-
toxoplasma gondii antibodies has been estimated in children with cryptogenic epilepsy 
and in two control groups, patients with secondary epilepsy and non-epileptic children. 
5.2.1. Study location, selection of subjects  
The Libyan health care system consists of public (funded by the government) and 
private health services. Public hospitals provide out-patient and in-patient services for 
the majority of children in our community. The setting of the study took place at the 
capital of Libya, Tripoli, located at west region of Libya, on the Mediterranean coast. 
Epileptic patients were selected from the National Center for the Treatment of Epilepsy 
in Tripoli city, which has an outpatient clinic for admission and follow up of patients 
with epilepsy. Children with a wide age range attend these clinics with their parents. 
Patients regularly receive their medication from the hospital pharmacy and a routine 
assessment of their condition is carried out periodically by specialists.  
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The controls were selected from the Tripoli Medical Center which is the largest hospital 
in the west region of Libya with 1200 beds.  
5.2.1.1. The National Center for the Treatment of Epilepsy 
The National Center for the Treatment of Epilepsy was built in 1997. It is one of the 
largest referral centres for patients with epilepsy in Libya. About 17000 patients 
including adults and children are registered with the center. About 9000 patients (52%) 
are from the Tripoli area and the rest are from urban and rural areas of western Libya. 
The records indicate that about 5000 of these patients probably have not had recurrences 
of epilepsy and could be considered cured.  
It has six outpatient clinics and eight specialist doctors in addition to twelve workers 
and nurses. There is a clinical laboratory to perform basic analytical determinations, 
including the determination of serum drug levels and also a separate EEG laboratory. 
The pharmacy distributes free anti-epileptic drugs to patients. It has an emergency room 
and IQ room to detect and follow the intellectual disability of patients. The center does 
not have radiology services to perform CT or MRI, therefore, the patient has to run 
these tests in public hospitals or private clinics. 
 
Figure 17: The National Center for the Treatment of Epilepsy 
  
Main gate                                                          EEG lab 
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Figure 18: The National Center for the Treatment of Epilepsy 
 
Patients Waiting Sala 
  
Clinical laboratory                                        Administrative archive 
  
Centre pharmacy 
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Figure 19: The National Center for the Treatment of Epilepsy 
   
Observation room                                         IQ room 
  
Epileptic Patient follows up 
 
5.2.1.2. Tripoli Medical Center  
The controls were selected from Tripoli Medical Center which is the largest teaching 
hospital in the west region of Libya with 1200 beds. It serves as a major reference 
centre for patients from the western division with a population of nearly two million. 
This centre offers all specialty services with advanced laboratory facilities. The control 
group of children were selected either consecutively from paediatric out-patient Clinics 
at Tripoli Medical Centre or opportunistically from children who had been admitted to 
the hospital in the Paediatric Department at the same hospital. 
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Figure 20: The Tripoli Medical Centre 
 
5.2.2. The study participants and inclusion criteria 
Study design considered three groups of children: 
 Group A: children with epilepsy (150 cases) divided in two subgroups. 
o A1: Suspected cryptogenic epilepsy (group name: Cryptogenic). 
o A2: Secondary epilepsy (group name: Symptomatic). 
 Group B: children without epilepsy (150 cases). 
Common inclusion criteria for all groups were: 
 Aged from 6 to 18 years old. 
 Absence of congenital syndromes/malformations. 
 Parents and children acceptance to participate in our project. 
5.2.2.1. Group A: children with epilepsy 
Children with epilepsy were sequentially recruited at The National Center for the 
Treatment of Epilepsy, Tripoli, Libya. Recruitment of these patients was made from 
March to July of 2014, when the patients arrived to follow up.  
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Patients with epilepsy who were candidates to be recruited for the study had a 
preliminary assessment of their suitability, excluding those with more probable genetic 
causes of epilepsy. If they were to participate in the study, they were assigned to the 
group of patients with cryptogenic or symptomatic epilepsy according to data collected 
from their clinical records and interview. The inclusion and exclusion criteria for both 
groups are described below. 
Finally, two of the 150 epileptic patients initially recruited were excluded because 
missed serum samples. 
5.2.2.1.1. Group A1: children with suspected cryptogenic epilepsy (Cryptogenic) 
Group-A1 finally includes 92 patients  
Specific inclusion criteria of this group were: 
- Epileptic children presented with recurrent epileptic fits with unknown aetiology. 
- All types of partial and/or generalized seizures 
- Patients had no past history of head trauma, brain surgery, meningitis or 
encephalitis. 
- Normal brain Magnetic Resonance Imaging Scan (MRI) and/or normal Computed 
Tomography Scan (CT). 
Exclusion criteria were: 
- Patients with seizure onsets under 6 years of age were excluded from this group. 
- Any disease with known relation with epilepsy. 
- Past history of perinatal hypoxia, difficult birth, head trauma, brain surgery, 
previous meningitis, encephalitis. 
- Abnormal brain Magnetic Resonance Imaging Scan (MRI) or abnormal Computed 
Tomography Scan (CT). 
- Family history of seizures. 
5.2.2.1.2. Group A2: children with secondary epilepsy (Symptomatic) 
Total of 56 patients suffering from symptomatic epilepsy were included in Group A2.  
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Specific inclusion criteria of this group were: 
- Presented with recurrent epileptic fits with known aetiology. 
- All types of partial and/or generalized seizures. 
- CT or MRI severe abnormalities that justify patient’s epilepsy. 
Exclusion criteria: 
- Congenital malformations o congenital syndromes. 
- Family history of seizures. 
5.2.2.2. Group B: non-epileptic children 
The 150 controls were enrolled from children attending the Tripoli Medical Centre for 
causes other than epilepsy. Most of these would include patients receiving a 
venepuncture for medical reasons and an aliquot of this sample would be requested for 
use as the control serum. Control patients selection was stratified by age groups (6-9 yr, 
10-13 yr, 14-17 years) for matching age distribution in Group A. 
Inclusion criteria of this group were: 
- Aged from 6 to 18 years old. 
- Neurologically normal 
- No history of seizures. 
Exclusion criteria 
- History of seizures in their first degree relatives. 
- Congenital malformations o congenital syndromes. 
5.2.3. Ethics approvals and consent 
The researcher obtained permission from the head department of National Epileptic and 
Centre Tripoli Medical Centre before making the field trip.  
A consent form added, that assuring participants that their confidentiality were 
respected and their anonymity guaranteed. In the current study, the participants were 
asked to indicate their name as an essential step which should be taken into serious 
consideration which was limiting the possibility of having their blood test results mixed 
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up with other patients. Participants were assured that either their acceptance or declining 
to participate in this study, would not affect their relationship with health center staff, 
their physicians or the care the children would receive. In addition, it was reported that 
if the child had Toxoplasma gondii infection, it will not be treated. 
Epileptic children have many barriers related to the socioeconomic circumstances of 
their families and social stigma. Particularly women are very conservative and reserved, 
being difficult to conduct interviews. During the interviews, I had to assure the patient 
and her parents that their answers were completely anonymous. This allowed them to 
feel comfortable and relaxed enough to speak freely. 
An information sheet was given in Arabic describing how this infection is acquired and 
the measures that can be taken to prevent it. 
5.2.4. Reporting of study result 
Usually parents of children wished to know the test results of their children. The results 
were copied and sent to clinical consultants in both the National Center for the 
Treatment of Epilepsy and the Infectious Disease Department in Tripoli Medical Center 
to allow them to inform parents who had requested the test result. 
5.2.5. Study procedure  
5.2.5.1. Variables and questionnaire survey 
The questioner was available in Arabic and English form. To ensure the cultural 
appropriateness of the questions and to guarantee that each question was fully 
understood, the questionnaire was designed and tested for its Arabic and English. All 
questionnaires had unique numerical identifiers. English questionnaires are shown in 
Appendix (Section 11.2).  
Patients questionnaires were filled out on the day blood samples were obtained. For the 
parents who didn’t know how to read or understand, the researcher read the questions 
and explains to them in simple way. 
The Questionnaire consists of three parts. In the first part questions are about the 
general socio demographic characteristics of the child and risk factors of toxoplasmosis, 
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the second part had questions directed at determining if they experienced perinatal 
complications. The third, part was about child development. 
Data recorded for epileptic children and controls included: 
- The Socio-demographic data including age, gender and residence. 
- History of blood transfusions. 
- Children habits and behaviours, including the kind of meat consumption (raw or 
undercooked), source of drinking water and milk, raw vegetables, personal hygiene 
and contact with soil, cats and dogs.  
- Perinatal complications. 
- Neurological development, such as age of walking independently, age of speaking 
and speak disorders, intellectual disabilities and education and academic success. 
For epileptic patients:  
- Medical antecedents, such as birth characteristics and complications, diseases, 
accidents and hospitalizations.  
- Neurological development, neurological deficits, intellectual capacity (IQ), visual 
and hearing impairments.  
- History and type of epilepsy including; age of onset, frequency and distinguishing 
features. 
- Cognitive development was assessed by psychologist using cognitive tests and 
recorded from medical file.  
- Results of brain MRI, CT and EEG (electroencephalogram). 
- Antiepileptic drugs usage and control of seizures. 
These data were obtained from interview and reviewing medical files for each patient.  
5.2.5.2. Interviews 
Interviews were completed by personal interview by the investigator. The procedure 
took about 10-15 minutes. For epileptic and control patient, this was done after clinic 
attendance.  
The medical records were then reviewed for completing medical information as EEG 
reports, brain imaging study reports and treatment.  
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Figure 21: Completing patient records 
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5.3. Toxoplasma gondii serology 
5.3.1. Serum collection an preservation 
Supplies for blood samples were available in both centres. A 5 ml sample of blood was 
collected from each child by a qualified medical technician under sterile conditions with 
minimum discomfort to participants. The samples were collected in a sterile Vacutainer 
with no additives and centrifuged.  
Serum was frozen and stored at -20ºC at the Tripoli Medical Center’s Clinical 
Immunology Lab until analysed for detection of Toxo-IgG antibodies. Maximum time 
elapsed to analysis was 4 months.  
 
Figure 22: Serum collection and preservation 
   
Cases study samples                                           Control study samples 
 
5.3.2. ELISA Assay Procedures   
Serum samples were screened for anti-T. gondii IgG  by ELISA using "Toxoplasma IgG  
kit” (DIESSE Diadnostica Senese. SPA 53035 Monteriggioni (SI) Italy). Procedure was 
conducted according to the manufacturer’s instructions. Positive and negative controls 
were used with each series of anti T. gondii IgG. Results were obtained at 450 nm 
absorbance. All these procedures were performed by the investigator with assistance of 
a laboratory technician at the Immunology Laboratory in Tripoli Medical Center. 
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Figure 23: Lab training 
   
Switch on instrument and Start-up program 
5.3.2.1. Material Required 
- Chorus Trio-81200 instrument. 
- Toxo-IgG kits with control and calibrator. 
- Sample rack. 
- Freezer and refrigerator  
- Micropipettes (50ul, 100ul & 1ml). 
- Laboratory glassware: cylinders and test tubes. 
- Disposable gloves. 
5.3.2.2. Quantification of anti-Toxoplasma IgG Antibodies 
Before starting the analysis, the Chorus system needs to setup the cleaning and washing 
buffer, then calibration procedure. Test is developed in individual disposable devices 
that include all necessary reagents (Figure 24). 
After fixing all devices in the Chorus instrument, 50μl of collected serum is added in the 
device.  
There are three steps involved to complete this enzymes immune assay:  
1. Conjugates with incubation (30 minutes). 
2. Wash three times.  
3. Stop reaction and quantification.  
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System spent approximately 140 minutes to finish results for 29 samples. The results 
were released automatically through the thermal printer in international units (IU/ml). 
 
Figure 24: Test device. 
 
 
Figure 25:  Device loading in tray 
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The degree of immunity of the test serum can be interpreted as follows: 
 Values higher than 12 IU/ml were considered positive.  
 Values lower than 8 IU/ml were considered negative.  
 Values from 8 to 12 IU/ml are considered indeterminate or doubtful 
 
Figure 26:  Results interpretation 
 
 
5.4. Data storage and handling 
Information collected was entered into a database using a coding system to anonymize 
the data collected. Access to the data was restricted to the project staff. Questionnaires 
and laboratory results were kept secure by the principle investigator. Firstly, data were 
entered into MS Excel. Data were checked manually to look for inconsistencies and 
outliers. Exploratory analysis was made using statistical software for final detection of 
mistakes.. 
5.5. Statistical analysis 
5.5.1. Hypothesis testing 
5.5.1.1. Bivariate data analysis 
Percentages of qualitative variables were compared by Chi-squared or Fisher’s exact 
test. Ordinal variables were compared with Mann-Whitney test or Kruskal-Wallis 
ANOVA. When applicable, continuous variables were compared by t-test or ANOVA. 
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Welch’s test was used for comparisons of continuous variables if assumption of 
homogeneity of variances was rejected. 
5.5.1.2. Multivariate data analysis 
Multivariate data analysis of risk factors was made with binomial logistic regression, 
with backward stepwise variable selection. Model fit was confirmed by ROC curve 
analysis of predicted values. 
5.5.1.3. Statistical significance level 
For null hypothesis significance testing, a threshold value for α = 0.05 cut-off was 
chosen. The null hypothesis was rejected when p < 0.05. Two-tailed contrasts were used 
for all comparisons. 
5.5.2. Data presentation 
Categorical data are shown as percentages. Continuous variables are resumed as mean 
±95% confidence interval (C.I.). Odds ratios (ORs) were shown with 95% confidence 
interval.  
5.5.3. Statistical software 
Statistical software programs used in this study were: 
  IBM SPSS Statistics: IBM Corp. Released 2013. IBM SPSS Statistics for 
Windows, Version 22.0. Armonk, NY: IBM Corp. 
 STATISTICA: StatSoft, Inc. (2014). STATISTICA (data analysis software 
system), Version 12.  
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6. RESULTS 
6.1. General introduction 
This chapter presents the results of the study. It begins describing the demographic 
characteristics and descriptive study of epileptic patients and control group. Third 
section shows results of toxoplasmosis serology, the analysis of socio-demographic and 
behavioural factors related with toxoplasma infection and relations of IgG anti-T. gondii 
results with study groups. The final section interprets the characteristics of epilepsy in 
studied patients and anti-Toxoplasma antibodies prevalence amongst patients and with 
different types of seizures.  
6.2. Subjects in study 
Were selected 300 participants (150 epileptic patients and 150 non-epileptic controls). 
Serum samples were missed in 2 epileptic patients. Finally, 298 cases were included in 
study.  
6.2.1. Whole group characteristics 
Their mean age was 11 ±3 years (range 6–17.5 years). Figure 27 shows age range and 
Table 4 shows distribution by age and sex groups.  
The majority of participants live in rural and sub urban areas 117 (39%), and 96 (32%) 
respectively. The lowest proportion was urban area 85 (28%), see Figure 29.  
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Figure 27: Age distribution in study subjects 
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Figure 28: Gender distribution in study subjects 
43%
57%
 
 
 
Female 
                       Male 
Mean: 11 ± 3 years 
Median: 11.1 years 
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Table 4: Cross-tabulation of gender and age 
Percentage by columns 
 
 
Figure 29: Residence 
Urban; 29%
Rural; 39%
Suburban; 32%
 
 
 
6.2.2. Epileptic patients: 148 cases 
Epileptic patients with congenital syndromes, known genetics base epilepsy, 
chromosomal abnormalities and first or second degree relatives affected of epilepsy 
were excluded at baseline.  
Included patients were initially classified into two groups, cryptogenic epilepsy and 
symptomatic epilepsy. 
 Age (years) Total 
6-<10  ≥10-<14  ≥14 
Male (column %) 68 (56.2%) 57 (58.8%) 45 (56.3%) 170 (57%) 
Female (column %) 53 (43.8%) 40 (41.2%) 35 (43.7%) 128 (43%) 
Total (row %) 121 (40.6%) 97 (32.6%) 80 (26.8%) 298 (100%) 
Rural: 40.3% 
Urban: 28.2% 
Suburban: 31.5% 
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6.2.2.1. Cryptogenic epilepsy: 92 cases 
These patients had normal brain MRI (91 cases) or CT (1 case). Cognitive assessment 
was made by psychologist technician and results are shown in Table 5. We lack of 
confirmation about what cognitive tests was performed in most of patients. Table 6 
shows walking and speaking age in this group. 
 
Table 5: Cognitive disability in patients with cryptogenic epilepsy 
 
 
Unknown test applied in most patients. 
 
Table 6: Speaking and walking age in patients with cryptogenic epilepsy 
 Minimum Maximum Mean S.D. 
Speaking age (months) 13 36 16,6 2,8 
Walking age (months) 9 15 11,8 1,7 
 
6.2.2.2. Symptomatic epilepsy: 56 cases  
Most of these patients had severe neurological disabilities. 84% had abnormal brain 
MRI or CT (Table 7). Table 8 shows aetiology of brain damage and epilepsy in this 
group. Only 20% can walk. Some kind of speaking disability was present in 47 (84%). 
Table 9 and Table 10 show intellectual and speaking disabilities in this group. 
 Frequency Percentage 
Normal 31 33,7% 
Mild intellectual disability 20 21,7% 
Moderate  intellectual disability 20 21,7% 
Not tested 21 22,8% 
Total 92 100% 
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Table 7: Aetiology of brain damage in patients with Symptomatic epilepsy 
 Frequency Percentage 
Birth related  20 35.7% 
Prematurity 13 23.2% 
Meningitis 10 17.9% 
Jaundice encephalopathy 3 5.4% 
Sepsis 2 3.6% 
Apnoea 2 3.6% 
Other 3 5.4% 
 
 
Table 8: CNS imaging in patients with Symptomatic epilepsy 
 Frequency Percentage 
PVL +/- hydrocephaly 15 26.8% 
PVL+SCL 9 16% 
IVHg IV+/- hydrocephaly 9 16% 
Hydrocephaly 5 8.9% 
Abnormal basal ganglia 3 5.4% 
Infarction 2 3.6% 
Multicystic encephalomalacia 2 3.6% 
Miscellaneous 2 3.6% 
Normal 9 16% 
PLV: periventricular leucomalacia ; SCL: subcortical lesion ; IVHg: intraventricular  
haemorrhage 
 
 
  
 
67 
Table 9: Cognitive disability in patients with Symptomatic epilepsy 
 
Unknown test applied in most patients. 
 
 
Table 10: Speaking disability in patients with Symptomatic epilepsy 
 Frequency Percentage 
Normal speech 9 16,1% 
Speechless 11 19,6% 
Mild dysarthria 14 25,0% 
Severe dysarthria 22 39,3% 
Total 56 100% 
 
6.2.2.3. Comparisons between epileptic patients 
6.2.2.3.1. Age and sex. 
Studied patients with symptomatic epilepsy had lower age at onset of seizures (Table 
11). Actual age was slightly lower in symptomatic epilepsy group. 
 
 
 Frequency Percentage 
Mild intellectual disability 13 23,2% 
Moderate  intellectual disability 14 25,0% 
Severe/very severe  intellectual disability 29 51,8% 
Total 56 100% 
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Table 11: Comparison between cryptogenic and symptomatic groups for age 
and onset of seizure 
 
There were no differences in gender between epileptic subjects. Gender proportions 
were M: 58.7% / F: 41.3% in cryptogenic epilepsy patients, and M: 62.5% / F: 37.5% in 
symptomatic epilepsy.  
6.2.2.3.2. Intellectual disability 
Most of epileptic patients were evaluated for cognitive status (Table 5 and Table 9). 
Figure 30 resumes intellectual status of both groups of epileptic patients.  
 
Figure 30:  Intellectual disability in epileptic patients 
 
 
 
0% 20% 40% 60% 80% 100% 
Cryptogenic 
Symptomatic 
20 
43 
51 
13 
moderate & 
severe 
normal & mild 
 Cryptogenic 
Mean ±SD 
Symptomatic 
Mean ±SD 
t-test 
p 
Age 11.74 ±3.25 10.37 ±3.06 <0.05 
Age at epilepsy onset (yr.) 8.16 ±2.63 3.86 ±2.41 <0.001 
Chi-squared: 
p<0.001 
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6.2.3. Non-epileptic controls: 150 cases 
Consecutive controls were selected at Tripoli Medical Centre General Paediatrics 
outpatient clinic and General Paediatrics hospitalization. These patients had no 
antecedents of seizures or any known neurological disease. Mean age was 11 years, SD 
3.3 years. Were Males: 54% and Females: 46 %. 
6.2.4. Demographic characteristics of study groups 
Table 12 resumes demographic characteristics of study groups. There were no 
differences in age, sex and residence between study groups. 
 
Table 12: Demographic characteristics of study groups 
Percentage by columns 
 
  
 Cryptogenic 
Epilepsy (N 92) 
Symptomatic 
Epilepsy (N 56)  
Non epileptic      
(N 150) 
p-value 
Age 
(years) 
6-9 34 (37%) 28 (50%) 59 (39%) NS 
10-13 30 (33%) 17 (30%) 50 (33%) 
14-17 28 (30%) 11 (20%) 41 (27%) 
Gender Male 54 (59%) 35 (63%) 81 (54%) NS 
Female 38 (41%) 21(38%) 69 (46%) 
Residence Urban 21 (23%) 18 (32%) 46 (31%) NS 
Suburban 29 (32%) 15 (27%) 52 (35%) 
Rural 42 (46%) 23 (41%) 52 (35%) 
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6.3.  Toxoplasmosis serology 
6.3.1. Prevalence of positive antibody titters  
Serum samples were screened with enzyme linked immunoassay for the presence of 
anti-Toxoplasma gondii IgG.  
Figure 31 shows anti-Toxoplasma  IgG titers for whole group. Titers under 8 IU/ml are 
considered negative, between 8 and <12 IU/ml are doubtful and titters ≥12 IU/ml are 
positive. The prevalence of toxoplasma infection in these children was close to 
expected, with 29.5% of IgG positivity.  
 
 
Figure 31: Anti-Toxoplasma IgG in epileptic children and controls 
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Titers <8 IU/ml are negative, 8-<12 IU/ml are doubtful and titters ≥12 IU/ml are positive. 
 
 
8 
Positive 29.5% 
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6.3.2. Socio-demographic characteristics related to Toxoplasma gondii 
infection 
6.3.2.1. Seroprevalence of toxoplasmosis according to age qroup 
Epileptic children and controls were divided in two age groups (6-<12 and 12-<18 
years). There were no differences in prevalence on infection or antibody titters between 
these groups (Figures 32 and 33). The prevalence of Toxoplasma gondii infection was 
28% for children of 6- to <12 years old and 31% in the older group (p=NS). 
There was no significant correlation between age and anti-Toxoplasma IgG titers 
(Spearman’s rank order correlation coefficient= 0.07; p=NS). 
 
 
Figure 32: Anti-Toxoplasma IgG antibodies by age groups 
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 Figure 33: Anti-Toxoplasma IgG titers by age groups 
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6.3.2.2. Seroprevalence of toxoplasmosis according to gender 
There was no difference in prevalence by gender. Females had positive IgG antibodies 
in 29% and males in 30% (Figure 34).  
 
Figure 34: Anti-Toxoplasma IgG antibodies by gender 
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6.3.2.3. Seroprevalence of toxoplasmosis according to residence  
In our study the proportion of children living in rural areas was slightly higher than 
those living in urban areas. However, there was no a statistically significant difference 
in prevalence of Toxoplasma gondii infection in relation to residential areas. Figure 35 
shows anti-Toxoplasma gondii IgG titers by place or residence. 
 
Figure 35: Anti-Toxoplasma IgG antibodies by residence 
suburban urban
rural
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6.3.2.4. Lifestyle risk factors  
Environmental exposure was analysed, including close contact with cats and soil, 
consumption of raw meat and vegetables, drinking untreated water or milk and personal 
hygiene habits (hands washing).  
 
Table 13: Lifestyle risk factors of Toxoplasma gondii infection I 
Variable Sero-negativity       
N (%) 
Sero-positivity     
N (%) 
P- value 
Eating raw meat 
Yes 
No 
 
18(39.1%) 
176(74.6%) 
 
28(60.9%) 
60(25.4%) 
 
<0.001 
Eating raw vegetables 
Yes 
No 
 
20(38.5%) 
174(75.7%) 
 
32(61.5 %) 
56(24.3%) 
 
<0.001 
Source of drinking water 
Public water source 
Alternative water source 
 
111(63.1%) 
83(78.3%) 
 
65(36.9%) 
23(21.7%) 
 
<0,01 
Drinking milk 
Unpasteurized 
Pasteurized 
 
31(61%) 
179(73%) 
 
20(39%) 
67(27%) 
 
NS 
Personal hygiene 
Yes 
No 
 
133(70.4%) 
61(65.6%) 
 
56(29.6 %) 
32(34.4%) 
 
N.S 
Contact with soil 
Yes 
No 
 
53(49.5%) 
141(80.6%) 
 
54(50.5%) 
34(19.4%) 
 
<0.001 
Percentage by rows 
Raw meat: frequent eating of raw or undercooked meat or homemade dried meat. 
Alternative water: drinking water from private wells or rain water deposits. 
Raw vegetables: frequent eating raw vegetables and fruits without disinfestation. 
Soil contact: frequent contact with soil without proper hands cleaning. 
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Table 14: Lifestyle risk factors factors of Toxoplasma gondii infection II 
Variable Sero-negativity       
N (%) 
Sero-positivity     
N (%) 
P- value 
Contact with cats 
Yes 
No 
 
33(43.4%) 
161(78.2%) 
 
43(56.6%) 
45(21.8%) 
 
<0.001 
Contact with house cats 
Yes 
No 
 
16(43.2%) 
178(72.7%) 
 
21(56.8%) 
67(27.3%) 
 
<0.001 
 
Neighbourhood cats 
Yes 
No 
 
20(36.4%) 
173(76.5%) 
 
35(63.6%) 
63(32.5%) 
 
<0.001 
 
More than two house cats 
Yes 
No 
 
10(62.5%) 
148(69.2%) 
 
6(37.5%) 
82(30.8%) 
 
N.S 
Contact with dogs 
Yes 
No 
 
17(68 %) 
177(68.9%) 
 
8(32%) 
88(31.1%) 
 
N.S 
Percentage by rows 
 
 
There were significant relations of Toxoplasma gondii infection with eating raw meat, 
eating raw vegetables and frequent contact with cats (Table 13 and Table 14). Drinking 
water from alternative water sources (private wells and rain deposits), although being 
generally untreated water sources, paradoxically showed some protective effect against 
T. gondii infection. 
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6.3.2.5. Blood transfusions 
Previous blood transfusions were not related to Toxoplasma gondii infection (Table 15). 
Table 15: Blood transfusions and Toxoplasma gondii infection 
Blood transfusions Sero-negativity      
N (%) 
Sero-positivity      
N (%) 
P- value 
Yes 
No 
10(83.3%) 
148(68.1%) 
2(16.7%) 
86(31.9%) 
N.S 
Percentage by rows 
6.3.2.6. Multivariate analysis of risk factors for Toxoplasma gondii infection 
Independent relations of demographical and environmental variables with infection with 
Toxoplasma gondii were explored by stepwise logistic regression. Table 16 shows 
independent risk factors for Toxoplasma gondii infection. 
  
Table 16: Risk factors for Toxoplasma gondii infection in study population 
(logistic regression coefficients) 
    OR 95% C.I. 
 ß 
coefficient 
p Odds ratio Lower 
limit 
Upper 
limit 
Raw meat 1.212 0.002 3.36 1.56 7.25 
Alternative water  -1.002 0.004 0.37 0.19 0.72 
Raw vegetables 1.408 0.000 4.09 1.87 8.93 
Soil contact 1.035 0.002 2.82 1.5 5.35 
Neighbourhood cats 1.756 0.000 5.79 2.82 11.91 
Raw meat: frequent eating raw or undercooked meat or homemade dried meat. 
Alternative water: drinking water from private wells or rain water deposits. 
Raw vegetables: frequent eating raw vegetables and fruits without disinfestation. 
Soil contact: frequent contact with soil without proper hands cleaning. 
Neighbourhood cats: presence of cats in neighbours (includes home cats). 
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Stepwise method was conditional backward selection. Cases with doubtful IgG titers 
were excluded. Table 18 shows independent risk factors for Toxoplasma gondii 
infection.  
Variables not included in model (not independently related with T. gondii 
seropositivity) were sex, age and age group, residence, drinking unpasteurized milk, 
blood transfusions, personal hygiene habits, contact with cats, and contact with dogs. 
Model Cox R
2
: 0.268; Nagelkerke R
2
: 0.378. Model classified correctly 79% of cases. 
Goodness of fit was evaluated with ROC curve analysis of predicted values (Figure 36). 
Area under the curve was 0.83 (95% confidence limits: 0.78-0.88). 
 
Figure 36: Risk factors for Toxoplasma infection. ROC curve of LR predicted 
values. 
 
 
  
AUC: 0.83 (0.78-0.88) 
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6.3.3. Relations of toxoplasmosis and epilepsy 
6.3.3.1. Comparing anti-Toxoplasma IgG between epileptic patients and non-
epileptic controls 
6.3.3.1.1.  Prevalence of T. gondii infection 
There were not differences in the prevalence of Toxoplasma gondii infection between 
epileptic children and non-epileptic controls (33,1% and 29,4% respectively). Cases 
with doubtful titers were excluded. (Figure 37) 
 
 
Figure 37: Prevalence of toxoplasma gondii infection in epileptic children and 
not-epileptic controls 
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6.3.3.1.2.  Antibody titers against T. gondii  
Figure 38 shows titers of IgG anti-T. gondii in epileptic patients and non-epileptic 
controls. There were not significant differences. 
 
 
 
Figure 38: Anti-Toxoplasma IgG titers in epileptic children and non-epileptic 
contols  
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Welch: p= NS 
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6.3.3.2. Comparing anti-Toxoplasma IgG within epileptic patients 
6.3.3.2.1. Prevalence of infection 
Figure 37 shows prevalence of Toxoplasma gondii infection in patients with cryptogenic 
epilepsy and patients with symptomatic epilepsy. Patients with doubtful titers (8-12 
IU/mL) were excluded. Differences were not significant. 
 
Figure 39: Anti-Toxoplasma IgG prevalence in epileptic patients. 
 
Patients with doubtful IgG titers (8-12 IU/mL) were excluded 
 
6.3.3.2.2. Titers of anti-Toxoplasma IgG 
Figure 40 shows titers of anti-Toxoplasma gondii IgG in patients with cryptogenic 
epilepsy and in patients with symptomatic epilepsy. Mean IgG titers were higher in 
patients with cryptogenic epilepsy (Cryptogenic epilepsy 24.7±7.6 IU/mL; Symptomatic 
epilepsy 15.3 ±5.8 IU/mL; Welch’s p<0.05). As maximum values detected were limited 
to 101 IU/mL this difference cannot be due to outliers’ effect.  
Percentage of patients with anti-toxoplasma IgG titers over 75 UI/mL was higher in 
cryptogenic epilepsy patients (Figure 41). 
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Figure 40: Anti-Toxoplasma IgG titers in epileptic patients. 
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Figure 41: High anti-Toxoplasma IgG titers in epileptic patients. 
 
Patients with doubtful IgG titers (8-12 IU/mL) were excluded. 
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Figure 42 shows exploratory plot of relationships between IgG titers with age and age at 
epilepsy onset. It shows some association between the age over 12 years and higher IgG 
titres that was confirmed posteriorly by logistic regression analysis.   
 
Figure 42: Relations of IgG titers with age and age at epilepsy onset. 
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6.3.3.3. Comparing toxoplasma infection between patients with cryptogenic 
epilepsy and controls without epilepsy 
6.3.3.3.1. Prevalence of Toxoplasma gondii infection 
There were no significant differences in prevalence of Toxoplasmosis between overall 
group of patients with cryptogenic epilepsy and non-epileptic controls (Figure 43). 
 
 
Figure 43: Prevalence of toxoplasmosis in patients with cryptogenic epilepsy and 
in non-epileptic controls. 
 
 
 
Patients with doubtful IgG titers (8-12 IU/mL) were excluded 
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6.3.3.3.2. Anti-Toxoplasma IgG titers 
Figure 44 shows mean anti-toxoplasma IgG titers of children with cryptogenic epilepsy 
and non-epileptic control. Patients with cryptogenic epilepsy had higher mean anti-
toxoplasma IgG titers than controls (cryptogenic epilepsy 24.7±8.4 IU/mL; controls 
16.1±4 IU/mL). This is due to increased rate of patients with high titers of anti-
Toxoplasma IgG in patients with cryptogenic epilepsy (Figures 45 and 46). 
 
 
 Figure 44: Anti-Toxoplasma IgG titers in patients with cryptogenic epilepsy and 
in non- epileptic controls. 
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Figure 45: Prevalence of high titers of anti-Toxoplasma IgG in patients with 
cryptogenic epilepsy and non-epileptic controls. 
 
 
Patients with doubtful IgG titers (8-12 IU/mL) were excluded. 
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6.4. Epilepsy 
This section resumes characteristics of epilepsy in studied patients. These patients are 
not representative of population of epileptic children in Libya. They were selected at 
only one treatment center and according to the objectives of this study. 
6.4.1. Type of seizures 
Types of seizures were grouped in main categories according to 2016 classification of 
ILAE. Classification shown is not exhaustive. 
There were differences in types of seizures between suspected cryptogenic epilepsy 
patients and patients with secondary epilepsy (Table 17, Figure 47 and 48). Absence 
seizures were present only in suspected cryptogenic epilepsy. 
 
Table 17: Type of seizures (% in columns). 
Type of seizures  Cryptogenic  Symptomatic  Total  
Focal  31 (33.7%) 24 (42.9%) 55 (37.2%) 
Generalized:    
- Absence  11 (12%) 0 (0%) 11 (7.4%) 
- Motor:    
           TC+T+C+At 32 (34.8%) 24 (42,9%) 56 (37.8%) 
           Myoclonic  18 (19.6%) 8 (14.3%) 26 (17.6%) 
Total  92 (100%) 56 (100%) 148 (100%) 
Percentage by columns 
Predominant seizures. TC: tonic clonic; T: tonic; C: clonic; At: atonic. 
Cryptogenic vs. symptomatic: Chi-squared, p<0.05 
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Figure 47: Type of seizures. 
Symptomatic
Myoclonic
Cryptogenic
Focal
Absence
Myoclonic
Focal
GTC/T/C/At GTC/T/C/At
 
GTC: generalized tonic clonic; T: tonic; C: clonic; At: atonic 
 
Figure 48: Types of focal seizures. 
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6.4.2. Control of seizures 
Figure 49 shows degree of seizure control in epileptic patients. Seizures’ control was 
categorized in four groups:  
 Complete remission: absence of seizures in 2 years. 
 Well controlled: absence of seizures in 6 months. 
 Partially controlled: some seizures in 6 months. 
 Poorly controlled: weekly or daily seizures. 
Patients with cryptogenic epilepsy had a better control of seizures than patients with 
secondary epilepsy, with less than 10% of poorly controlled seizures (Figure 47). 
Figure 48 shows need of combination therapy in children with cryptogenic epilepsy and 
in symptomatic epilepsy. Patients with symptomatic epilepsy had a higher percentage of 
children needing 3 drugs.  
 
Figure 49: Degree of seizures control in epileptic patients. 
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 Figure 50: Number of antiepileptic drugs required in patients with cryptogenic 
and symptomatic epilepsy. 
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6.4.3. Toxoplasmosis and control of seizures: 
Possible relation of infection by Toxoplasma gondii and control of seizures was 
explored. Table 18 and Table 19 show relation of toxoplasmosis and control of seizures 
and number of antiepileptic drugs. No relation was found between these variables and 
toxoplasma infection. 
 
Table 18: Toxoplasma infection and control of epilepsy 
Mann-Whitney: p=NS 
 
Table 19: Toxoplasmosis and number of antiepileptic drugs 
 Nº antiepileptic drugs 
Anti-Toxoplasma ab.    1 2 ≥3  
Negative 53 (57%) 27 (29%) 13 (14%) 
Positive 27 (58.7%) 11 (23.9%) 8 (17.4%) 
Mann-Whitney: p=NS 
  
 Control of epilepsy 
Anti-Toxoplasma ab.  Complete 
remission 
Well 
controlled 
Partially 
controlled 
Poorly 
controlled 
Negative 15 (16.1%) 18 (19.4%) 46 (49.5) 14 (15.1) 
Positive 6 (13%) 12 (26.1%) 20 (43.5%) 8 (17.4%) 
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6.4.4. Toxoplasmosis seroprevelance and type of seizures 
Table 20 and 21 shows relations between the type of epileptic seizures and prevalence 
of Toxoplasma gondii infection. Patients with focal seizures had a higher rate of 
infection by Toxoplasma gondii (Figure 51 and 52). Figure 53 shows a more detailed 
distribution of seizure types and its relation with toxoplasma seropositivity. Patients 
with doubtful anti-Toxoplasma IgG titers were excluded. 
 
Table 20: Toxoplasmosis seroprevelance and type of seizures I 
Type of seizures Positive Negative Chi-squared 
p value 
Generalized  22 (29%) 66 (71%) <0.05 
Focal 24 (47.1%) 27 (52.9%)  
Percentage by row 
 
Table 21: Toxoplasmosis seroprevelance and type of seizures II 
 
Type of seizures 
 
Anti-Toxoplasma ab. result     A  GTC  M  F  Total  
Negative 
 
Count  8 
 
37 
 
21 
 
27  
 
93 
 
% within column  80 %  
 
71.2 %  
 
80.8 %  
 
52.9 %  
 
66.9 %  
 
Positive 
 
Count  2 
 
15  
 
5  
 
24  
 
46 
 
% within column  20 %  
 
28.8 %  
 
19.2 %  
 
47.1 %  
 
33.1 %  
 
Total  
 
Count  10 
 
52  
 
26 
 
51 
 
139 
 
% within column  100%  
 
100%  
 
100 %  
 
100 %  
 
100%  
 
A: absence seizures. GTC: generalized, tonic clonic, tonic, clonic and atonic seizures. M: 
myoclonic seizures. F: focal seizures. 
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Figure 51: Relation of anti-Toxoplasma IgG in epileptic patients to type of 
seizures. 
Focal
24
27
Absence
2
8
GTC/T/C/At
15
37
Myoclonic
5
21
 
 
Patients with doubtful IgG titers (8-12 IU/mL) were excluded 
 
 
 
 
 
 
Positive       
Negative 
 
 
 
 
 
 
                           
 
 
 
  
 
93 
 Figure 52: Relation of anti-Toxoplasma IgG positivity to type of seizures. 
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Figure 53: Prevalence of Toxoplasma gondii infection in epileptic patients with 
focal seizures. 
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6.4.4.1. Prevalence of toxoplasma infection by type of seizure and CNS imaging 
results 
There were no significant differences in prevalence of Toxoplasma gondii infection 
between epileptic patients with normal or abnormal CNS imaging. Figure 54 shows 
frequency of TG infection by seizure type and results of CNS imaging. 
  
Figure 54: Prevalence of Toxoplasma gondii infection in epileptic patients. 
Combined effect of type of seizures and results of CNS imaging.  
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Table 22 resumes some characteristics of patients with focal seizures and abnormal 
MRI. Periventricular leukomalacia was the abnormality diagnosed in most of these 
patients. 
 
Table 22: Patients with focal epilepsy and abnormal CNS imaging 
Age (yr) Epilepsy 
onset (yr) 
Brain MRI Speech disability Toxoplasma 
IgG 
9,7 2,5 PVL Mild Negative 
12,6 1,1 PVL II Mild Negative 
12 8,9 PVL Mild Negative 
14,3 2 PVL Normal speech Negative 
13,5 4 PVL + SCL Severe Negative 
11,4 4 Miscellaneous Severe Negative 
8,3 2 Basal ganglia Speechless Negative 
15 4 PVL + SCL Severe Negative 
6,7 1 IVHg III Severe Negative 
11,4 4 IVHg II Mild Positive 
11,9 2,5 PVL I Normal speech Positive 
14 6 IVHg Mild Positive 
14 5 PVL Normal speech Positive 
6,5 1 PVL Normal speech Positive 
8 8 Infarction Mild Positive 
6 2 PVL Severe Positive 
6,2 0,9 PVL + SCL Speechless Positive 
12,6 5 BIL PVL Severe Positive 
PVL: periventricular leukomalacia; SCL: subcortical lesions; IVHg: intraventricular 
haemorrhage; BIL: bilirrubin encephalopaty. 
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6.4.5. Multivariate analysis of relationships of epilepsy with toxoplasma 
gondii infection 
6.4.5.1. Variables related to Toxoplasma gondii infection in all subjects studied 
Logistic regression analysis was utilized to identify variables independently related to 
Toxoplasma gondii infection. Dependent variable was positivity or negativity of anti-
Toxoplasma IgG. Patients with doubtful titers were excluded. Selection method was 
backward stepwise exclusion. 
Five dummy variables were created as follows and included in all regression analysis: 
1. Symptomatic epilepsy:  Yes=1, No=0. 
2. Cryptogenic epilepsy:  Yes=1, No=0. 
3. Non-epileptic controls:  Yes=1, No=0. 
4. Focal seizures:  Yes=1, No=0. 
5. Other seizures:  Yes=1, No=0. 
6.4.5.1.1. Variables related to Toxoplasma gondii infection, without considering behavioral risk 
factors 
Other variables included in this analysis were age group, sex, speech disability and 
residence.  
Logistic regression results: 
The only variable selected in logistic regression equation was “Focal seizures”, which 
was positively related to Toxoplasma gondii infection (Table 23). Model Cox R
2
: 0.024; 
Nagelkerke R
2
: 0.034.  
 
Table 23: Factors related to Toxoplasma gondii infection (logistic regression 
coefficients) 
    OR 95% C.I. 
 ß coefficient p Odds ratio Lower 
limit 
Upper 
limit 
Focal seizures 0.84 0.008 2.32 1.25 4.32 
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6.4.5.1.2. Variables related to Toxoplasma gondii infection, adjusted by behavioral risk factors 
Other variables included in this analysis were age group, sex, speech disability, 
residence, eating raw meat, eating raw vegetables, alternative source of drinking water, 
drinking unpasteurized milk, contact with soil, personal hygiene, contact with cats, and 
neighbourhood cats.  
Logistic regression results: 
Table 24 shows regression analysis results. After adjustment by behavioural risk factors, 
“Focal seizures” continues to be independently related to Toxoplasma gondii infection. 
 
Table 24: Factors related to Toxoplasma gondii infection, including behavioral 
risk factors (logistic regression coefficients) 
    (Exp ß) 95% C.I. 
 ß 
coefficient 
p Odds ratio 
(Exp ß) 
Lower 
limit 
Upper 
limit 
Focal seizures 1.011 0.010 2.75 1.27 5.94 
Raw meat 1.151 0.004 3.16 1.44 6.94 
Alternative water  -1.028 0.003 0.36 0.18 0.71 
Raw vegetables 1.566 0.000 4.79 2.12 5.16 
Soil contact 0.985 0.003 2.68 1.39 5.16 
Neighbourhood cats 1.779 0.000 5.92 2.85 12.32 
Raw meat: frequent eating raw or undercooked meat or homemade dried meat. 
Alternative water: drinking water from private wells or rain water deposits. 
Raw vegetables: frequent eating raw vegetables and fruits without disinfestation. 
Soil contact: frequent contact with soil without proper hands cleaning. 
Neighbourhood cats: presence of cats in neighbours. 
 
 
Model Cox R
2
: 0.285; Nagelkerke R
2
: 0.401. Model classified correctly 78.9 % of 
cases. 
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6.4.5.2. Variables related to Toxoplasma gondii infection in epileptic patients 
6.4.5.2.1. Without behavioral risk factors: 
In this analysis, non-epileptic controls were excluded. The dependent variable was 
positivity of anti-Toxoplasma IgG. Patients with doubtful titers were excluded.  
For analysing the effect of the type of epilepsy, four dummy variables were created and 
coded as follows:  
1. Focal seizures:      Yes=1, No=0. 
2. Generalized absence seizures:    Yes=1, No=0. 
3. Generalized myoclonic seizures:    Yes=1, No=0. 
4. Generalized tonic clonic, tonic, clonic or atonic seizures:  Yes=1, No=0. 
Degree of epilepsy control was coded in three dummy variables: 
1. Remission of seizures: Yes=1, No=0. 
2. Not well controlled:  Yes=1, No=0. 
3. Poorly controlled:   Yes=1, No=0. 
Other variables included in this analysis were age, age group, sex, age at epilepsy onset, 
number of antiepileptic drugs. Variable selection method was backward stepwise 
exclusion. 
Logistic regression results: 
Only “Focal seizures” was independently related to Toxoplasma gondii infection (Table 
25). Characteristics of model were: Cox R
2
: 0.049; Nagelkerke R
2
: 0.068.  
 
Table 25: Factors related to Toxoplasma gondii infection in epileptic children 
(logistic regression coefficients) 
    (Exp ß) 95% C.I. 
 ß 
coefficient 
p Odds ratio 
(Exp ß) 
Lower 
limit 
Upper 
limit 
Focal seizures 0.981 0.009 2.67 1.28 5.54 
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6.4.5.2.2. Adjusting for behavioural risk factors. 
In this analysis, behavioural risk factors were added to the previous set of variables: 
eating raw meat, eating raw vegetables, alternative source of drinking water, drinking 
unpasteurized milk, contact with soil, personal hygiene, contact with cats, and 
neighbourhood cats.  
Logistic regression results: 
After adjustment by the effect of behavioural risk factors, “Focal seizures” continues to 
be independently related to Toxoplasma gondii infection. “Absence seizures” and 
“Remission of seizures” were negatively related to Toxoplasma gondii infection. Other 
variables selected were those previously identified as behavioural risk factors, but it is 
of interest that eating raw vegetables, contact with soil and presence of neighbourhood 
cats had higher odds ratios in epileptic children than in the whole group (Table 26). 
 
Table 26: Factors related to Toxoplasma gondii infection in epileptic children, 
including behavioral risk factors (LR coefficients)  
    (Exp ß) 95% C.I. 
 ß 
coefficient 
p Odds ratio 
(Exp ß) 
Lower 
limit 
Upper 
limit 
Focal seizures 1.167 0.040 3.21 1.05 9.80 
Absence seizures -2.607 0.052 0.07 0.01 1.00 
Remission of seizures -2.334 0.009 0.10 0.02 0.55 
Raw meat 1.708 0.019 5.52 1.33 22.88 
Alternative water  -1.489 0.012 0.23 0.07 0.72 
Raw vegetables 3.028 0.001 20.66 3.70 115.23 
Soil contact 2.427 0.000 11.32 3.54 36.18 
Neighbourhood cats 2.475 0.000 11.89 3.01 46.96 
Raw meat: frequent eating raw or undercooked meat or homemade dried meat. 
Alternative water: drinking water from private wells or rain water deposits. 
Raw vegetables: frequent eating raw vegetables and fruits without disinfestation. 
Soil contact: frequent contact with soil without proper hands cleaning. 
Neighbourhood cats: presence of cats in neighbours. 
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Model characteristics were: Cox R
2
: 0.442; Nagelkerke R
2
: 0.615. Model classified 
correctly 84.7% of cases. 
6.4.5.3. Variables related to high titers of anti-Toxoplasma IgG 
Dependent variable was titers of anti-Toxoplasma IgG ≥ 75 UI/ml. All cases, including 
those with doubtful titers, were included. Selection method was backward stepwise 
exclusion.  
Following dummy variables were included: 
 Symptomatic epilepsy:  Yes=1, No=0. 
 Cryptogenic epilepsy:  Yes=1, No=0. 
 Non-epileptic controls:  Yes=1, No=0. 
 Focal seizures:  Yes=1, No=0. 
 Generalized seizures: Yes=1, No=0. 
Other variables included in this analysis were age group, sex, speech disability, 
residence and behavioural risk factors (eating raw meat, eating raw vegetables, 
alternative source of drinking water, drinking unpasteurized milk, contact with soil, 
personal hygiene, contact with cats, and neighbourhood cats).  
 
Logistic regression results: 
Age group 12-18 years and cryptogenic epilepsy were independently and positively 
related with high titers of anti-Toxoplasma IgG. Behavioural risk factors had the same 
“behaviour” as in previous analysis (Table 27).  
This predictive model had good properties. Model Cox R
2
: 0.447; Nagelkerke R
2
: 
0.621. Model classified correctly 85% of cases.  
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Table 27: Factors related to high titers of anti-Toxoplasma IgG, including 
behavioral risk factors (logistic regression coefficients) 
    (Exp ß) 95% C.I. 
 ß 
coefficient 
p Odds ratio 
(Exp ß) 
Lower 
limit 
Upper 
limit 
Age group 12-18 yr. 1.112 0.027 3.04 1.13 8.15 
Cryptogenic epilepsy 1.007 0.037 2.74 1.06 7.04 
Raw meat 1.069 0.028 2.91 1.12 7.53 
Alternative water  -1.159 0.045 0.31 0.10 0.97 
Raw vegetables 1.134 0.029 3.11 1.12 8.60 
Soil contact 2.546 0.000 12.76 4.26 38.23 
Contact with cats 1.112 0.027 3.04 1.13 8.15 
Raw meat: frequent eating raw or undercooked meat or homemade dried meat. 
Alternative water: drinking water from private wells or rain water deposits. 
Raw vegetables: frequent eating raw vegetables and fruits without disinfestation. 
Soil contact: frequent contact with soil without proper hands cleaning. 
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7. DISCUSSION 
7.1. Study design 
The design of our study in three groups was similar to that of the Yazar and Eraky 
studies. In both cases, a group of patients with cryptogenic epilepsy was compared with 
non-epileptic controls and with patients with symptomatic epilepsy (Yazar et al. 
2003)(Eraky et al. 2016).  
Most studies compared the prevalence of T. gonddi infection between epileptic subjects 
and healthy controls. Babaie et al. compared the seroprevalence of toxoplasmosis in 
epileptic patients and two control groups, a group of neurological patients without 
epilepsy and another group of healthy controls (Babaie, et al. 2017).   
We hypothesized that cases of toxoplasmosis-related epilepsy would be concentrated in 
patients with cryptogenic epilepsy. Thus, when comparing the prevalence in patients 
with cryptogenic epilepsy with that of other groups, would be easier to demonstrate any 
possible relation of T. gondii infection with epilepsy. 
7.1.1. Were epileptic patients correctly classified?  
The classification of patients in suspected cryptogenic and secondary epilepsy was 
based on the usual criteria (Shorvon 2011). First, some genetic causes of epilepsy were 
excluded by ruling out patients with a family history of epilepsy and any known 
congenital syndrome. Patients with alterations in brain imaging, history of CNS lesions 
or diseases, histories suggesting perinatal hypoxic-ischemic encephalopathy or cerebral 
palsy were classified as secondary epilepsy. But there were some patients diagnosed of 
rolandic epilepsy and juvenile myoclonic epilepsy, diseases of known genetic influence 
that were maintained in cryptogenic group. 
Patients were classified as suspected cryptogenic epilepsy when there were no 
alterations in brain imaging tests and no history of CNS lesions, CNS diseases or 
perinatal complications. In order to rule out febrile seizures, patients with onset of 
seizures before 6 years of age were excluded of this group.  
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In this study there are several elements used for the classification of patients that are not 
completely reliable. The National Center for the Treatment of Epilepsy is not a general 
hospital, but a monographic clinical center. Therefore, patients' clinical records are 
limited to the information that the parents have provided, verbally or with the reports 
provided. There are no medical records that refer to childbirth and perinatal period. It 
has no radiological facilities. Brain imaging tests were performed at other public and 
private health centers, often located in adjacent countries, mainly Egypt and Tunisia, 
leaving only a copy of the report in the medical record. The cultural level of most of the 
families served is medium and low, so descriptions of medical history are not always 
very accurate.  
In the National Center for Treatment of Epilepsy there was a cognitive evaluation 
laboratory, where a technician performed cognitive tests on patients in recent years. 
Thanks to this, an assessment of the intellectual development of the majority of patients 
is available. This assessment was generally consistent with the degree of clinically 
evident intellectual disability. The name of the test used in each patient was not initially 
recorded and it was not possible to verify it later. It has been found that at least the 
"WISC test" and the "Raven matrix test" were used. For these reasons, the information 
derived from the degree of intellectual disability of the patients has not been included in 
this thesis. 
Within patients with suspected cryptogenic epilepsy, 21% of patients had a "moderate 
intellectual disability". The term "moderate intellectual disability" corresponds to an 
intellectual quotient (IQ) between 35% and 55% of normal (100%), a really important 
deficit (American Psychiatric Association 1994).  The degree of cognitive deficit found 
in children with idiopathic epilepsy and cryptogenic epilepsy in developed countries is 
generally very mild. The IQ found in the majority of the studies performed in these 
patients are within the normal range (IQ ≥85) or are kept within the limits of the 
Intellectual Function Limit (IQ of 71-84) (Reijs et al. 2007; Van Mil et al. 2008; 
Oostrom et al. 2005). In Connecticut (US), only 2% of patients with idiopathic epilepsy 
and cryptogenic epilepsy had IQs below 60. In contrast, in children with secondary 
epilepsy, major cognitive deficits were more frequent (36%) and more severe (Berg et 
al. 2008). Therefore, we suspect that some patients classified as cryptogenic epilepsy 
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may not be, making it more difficult to detect any difference between both groups of 
epileptic patients and with non-epileptic controls. 
Lagunju and colleagues studied intellectual development in 40 Nigerian children with 
newly diagnosed epilepsy, with no known cause of epilepsy (Lagunju et al. 2016). The 
causes of secondary epilepsy were ruled out exclusively by the antecedents referred by 
their parents. Assessment of IQ at the onset of epilepsy using the WISC-IV found 
moderate disability (IQ 35-55) in 27% and severe disability in 3%, together with poor 
school performance in 47% of cases, prior to the onset of epilepsy. It is likely that in 
developing countries, without advanced perinatal care and without adequate resources 
for the early detection of intellectual disability in children, many patients with 
secondary epilepsy of perinatal origin may be classified as idiopathic or cryptogenic 
epilepsy. 
7.2. Subjects in study 
7.2.1. Socio-demographic characteristics  
Studies about prevalence of toxoplasmosis targeting epileptic children are scarce. Only 
Potasman (Israel), El Tantawy (Egypt) and Eraky (Turkey) conducted studies on the 
prevalence of Toxoplasma gondii infection in children with epilepsy (Potasman et al. 
1995)(Labeeb El-Tantawy et al. 2013)(Eraky et al. 2016). Ngugui analysed separately 
the prevalence of toxoplasmosis among children under 18 years of age in their study in 
5 Sub-Saharan African countries, the largest study in children to date, with 416 cases 
and 599 controls, but did not found any significant differences in the prevalence of 
toxoplasmosis between both groups (Ngugi et al. 2013). 
Previous studies included children younger than 6 years, in contrast to our study. 
Children with onset of seizures before 6 years of age were excluded in the cryptogenic 
epilepsy group, in order to eliminate cases with secondary epilepsy and simple febrile 
seizures. 
The case and controls were similar in terms of socio-demographic characteristics; there 
were insignificant differences between the three groups studied in terms of age, sex and 
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residence. In the present study, epileptic patient’s residence was higher in rural areas 
(44%) than in urban ones (26%). 
The male / female ratio of children included in this study was 1.5: 1. A total of 59% of 
cryptogenic and 63% of symptomatic epileptics were male. Female were 41% of 
cryptogenic and 38% of symptomatic epileptic children. Also a higher male rate was 
present in the study of El Tantawy in Egyptian children (El-Tantawy et al. 2013), but 
Eraky et al. reported a slightly higher rate of females (Eraky et al. 2016). It is 
improbable that these small differences does affect to the results. 
7.2.1. Epileptic patients 
Study included a total of 148 epileptic participants followed up for epilepsy at National 
Centre for treatment of Epilepsy. These patients were further divided into two 
subgroups on the basis of epileptic cause; suspected cryptogenic epilepsy 92 (31%) 
considered as cases (group A1) and symptomatic epilepsy 56 (18.8%) considered as 
controls (group A2). Mean age was slightly higher in cryptogenic epilepsy patients than 
in symptomatic epileptics (11.7 and 10.4 respectively). Small mean age differences 
should not influence comparisons between groups.  
7.2.2. Cryptogenic epilepsy 
In children with cryptogenic/idiopathic epilepsy cognitive function is usually within 
normal range but tends to be lower than the general population. Impaired cognitive 
function in epileptic children is associated with young age at epilepsy onset, underlying 
pathology, anti-epileptic drugs (AEDs) use (Berg et al. 2008), frequency of seizures and 
type and  duration of epilepsy (Lopes et al. 2013).  
In our study, almost 22% had moderate cognitive impairment. This finding was 
surprising. Her motor and neuroimaging tests were normal. Probably, the neuroimaging 
studies performed had very limited value in the establishment of a specific diagnosis. 
We believe that that some of these patients could have symptomatic epilepsies of 
perinatal origin. Without a thorough record of their perinatal history, some patients with 
symptomatic epilepsy could be classified as cryptogenic or idiopathic epilepsy. 
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7.2.3. Symptomatic epilepsy 
Fifty-six children with symptomatic epilepsy were considered as controls. These 
patients had a history suggestive of underlying brain insult or had abnormal brain 
imaging. Inherited factors and abnormal perinatal history increases the risk of 
developing epilepsy by 3.2-folds (Senanayake & Román 1993). Therefore, 
complications in perinatal period which start from labor, through delivery, and up to the 
end of the first week after delivery were also taken in consideration in questionnaire.  
History of prenatal period was excluded from the study. The aetiologies of 
symptomatic epilepsy were birth related cause in 36% followed by prematurity and 
meningitis 23%, 18% respectively, close to those of other similar studies in neighbour 
countries. In one study, the causes of symptomatic epilepsies in Saudi Arabia were pre 
or perinatal encephalopathy, head injury, childhood neurological infection and stroke 
(Al Rajeh et al. 2001).  
Only 9 patients (16%) had normal brain imaging (Table 8). The majority of children in 
this group (77%) had moderate to severe cognitive impairment. Cognitive function 
regarded as mildly impairment in 23%, in concordance with other studies reported in 
Africa (Abas et al. 2017). In children with symptomatic epilepsy, the level of cognitive 
function is strongly associated with underlying brain injury, neurologic problems and 
early onset of seizures (Andersen et al. 2008). 
7.2.4. Non epileptic subjects  
We selected 150 non epileptic subjects who were otherwise neurologically normal. 
Included 81 (54%) male and 69 (46%) girls aged from the same geographic distribution 
and of approximately the same age. The mean age was (11 ± 3.3) years, Nearly the 
same proportion of participants were from rural, sub urban and urban areas 46 (31%) 
and 52 (35 %) respectively. Exclusion criteria for controls were a history of epilepsy in 
their first degree relatives It should be noted. The controls were enrolled from children 
attending the Tripoli Medical Centre for causes other than epilepsy. These would include 
patients receiving a venipuncture for medical reasons and an aliquot of this sample would 
be requested for use as the control serum. 
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7.3. Toxoplasmosis serology 
In current study, the overall seroprevalence of T. gondii infection among Libyan 
children was close to expected, with 29% of IgG positivity. The seroprevalence 
recorded in this study was lower than the values previously reported for schoolchildren 
of nearly similar ages (7-18 years) in Libya. Khadre and El Nageh (1987) reported a 
seropositive rate of 43.7% (Khadre & El Nageh 1987). Toxoplasma seroprevelance in 
mentally retard Egyptian children was 43.75% (Amrei et al. 1999), which is higher than 
in the present study. Furthermore the overall prevalence raised from 24.5% at ten years 
to 52.1% at 20 years of age in Tunisia (Bouratbine et al. 2001). Seroprevalance of 
toxoplasmosis among Iranian children was 10% (Ali et al. 2007) and Greek 6-15 years 
old children had an infection rate of around 11% (Frydas et al. 2000), both are lower 
than our findings.  
The study showed that 12% of children had high serum anti-TG IgG antibody levels 
(titers ≥50 IU/ml). High titers of anti-Toxoplasma antibodies are regarded as suggestive 
of the occurrence of either recent infection and (Kook et al. 1999), or reactivations of  
parasite from encysted bradyzoites to circulating tachyzoites (Fu et al. 2014). 
7.4. Factors related to Toxoplasma gondii infection 
Toxoplasma infection is related to several  factors  including  socioeconomic  level, 
nutritional  habits, age and rural or urban setting (Spalding et al. 2005). 
Generally, children are particularly more vulnerable to toxoplasmosis infection due to 
their behavioural habits. They have higher environmental exposure and a lack of 
awareness for avoiding these risk factors such as playing in water, soil, eating various 
raw foods, or contact with pets.  Hence they are an ideal target group to investigate 
toxoplasmosis prevalence (Fan et al. 2012). 
7.4.1. Socio-demographic factors 
Sero-epidemiological surveys have revealed varying degree of prevalence in terms of 
different geographical settings and the risk factors for acquiring the disease age 
distribution, climate and socio-economic status (Bahia-Oliveira et al. 2003).  
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We have not found significant relation between socio-demographic factors and 
prevalence of Toxoplasma gondii infection in studied children. The same result was 
obtained when we include the doubtful results as positives in the analysis. 
7.4.1.1. Age 
Seroprevalence of toxoplasmosis is known to increase with age that is a reflection of 
increasing risk of exposure with age (Jones et al. 2009). In this study, there were not 
significant changes in prevalence in studied patients. Seroprevalence was 32% in 12-
<18 year-old group and 28% in children aged 6-<12 years. Chung-Jung Fu et al. (2014) 
observed that infection rates declined with age (Fu et al. 2014).  
In our study, mean anti-Toplasma IgG titter was slightly higher in age group of 12-<18 
years old (21.2 IU/ml) than in age group 6-<12 years old (16.6 IU/ml), but there was no 
significant differences. Higher age group was positively related to anti-Toplasma IgG 
titers >75 UI/mL in logistic regression analysis. 
In consistant to our study, Babaie et al. (2017) reported that the IgG titer of anti-T. 
gondii antibodies significantly increased with age, with Pearson's correlation coefficient 
value of +0.254 (Babaie et al. 2017). The IgG titer for ≤ 30, 31-40, 41-50 and ≥ 51 years 
of age groups were found as 44.6 ±76, 54.4 ±74, 74.8 ±77 and 106.3 ±84 UI/mL 
respectively. In contrast to another study among primary schoolchildren in Taiwan, that 
found significant increased titer of anti-Toxoplasma gondii antibodies in younger age 
group (Fu et al. 2014). 
7.4.1.2. Gender 
Our study does not found significant gender difference in seroprevalence (boys 30%, 
girls 28.9%). It might be because both genders are having similar routes for acquisition 
of T. gondii infection (Fan et al. 2012). Although, Akyol et al. found increased 
prevalence in Iranian boys (Akyol et al. 2007). 
7.4.1.3. Area of residency 
Sero-positivity was almost the same among residents in rural, suburban and urban areas; 
31%, 30% and 27% respectively. This coincides with Zibaei et al. (2011), who did not 
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find significant differences between the seroprevalence of T. gondii infection in rural 
areas compared to urban areas (Zibaei et al. 2011). This can be explained by various 
risk factors associated with T. gondii infection that have the same distribution in urban 
and rural areas. This is in consistent with other studies in north Africa (el-Nawawy et al. 
1996)(El-Tantawy et al. 2013).   
7.4.2.   Life style risk factors of Toxoplasma gondii infection 
In the bivariate analysis, five variables were identified as possible risk factors for 
toxoplamosis (Table 13 and 14): Eating raw meat, Eating raw vegetables, Source of 
drinking water, Contact with soil and Contact with cats (house cat, neighbourhood cat). 
Further analysis using multivariate logistic regression revealed that all variables found 
statistically significant in the bivariate analysis kept the statistical significance in the 
multivariate model (Table 16).  
7.4.2.1. Raw meat or under cooked meat consumption  
Raw or undercooking meat consumption was positively associated with Toxoplasma 
gondii infection in our study. Children who eat raw meet were 3.36 times at higher risk 
of being seropositive than children who were not.  In Libya, lamb, goat, beef, camel and 
chicken meat are commonly used. Pork is never used due to religious ban. It is well 
documented that lamb and goat meat are sources of T. gondii (Dubey 2000). Generally, 
thorough cooking is always preferred in Libya. However, raw meat is also consumed in 
traditional food as "kaedid” which is dry salty raw meats and undercooked meat at a 
barbecue. Consumption of raw meat or undercooked meat can serve as a route of 
infection in our study. This result is similar to that done in children from a Brazilian 
rural area (Souza et al. 1987). While ingestion of raw meat appeared to play no role in 
transmission in Panamanian children (Frenkel et al. 1995).  
7.4.2.2. Raw vegetables (how often the child eats vegetables) 
Contaminated fruit and vegetables probably by cat faeces and poor hand hygiene also 
are important in parasite transmission in our study. Children who frequently eat raw 
vegetable were 4 times more likely to be seropositive compared to who didn’t eat it. 
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Which coincides with studies from Cameroon and China (Njunda et al. 2011)(Xin et al. 
2015). 
In epileptic children, frequent eating of raw vegetables had an increased excess risk of 
Toxoplasma gondii infection, with odds ratio of 20.66 (Table 26: OR 20.66; 95% CI 
3.7-115), thus being a major risk factor of toxoplasmosis infection in our study.  
7.4.2.3. Source of drinking milk 
Non-processed milk from several animals is a potential source of T. gondii transmission 
(Sacks et al. 1982)(Dubey et al. 2014). Contamination of milk might be due to dirty 
production techniques. Or it may be related to other lifestyle risk factors such as eating 
undercooked meat or hygienic habits (Cook et al. 2000). Generally, most of population 
consumes pasteurized milk. However, the consumption of raw milk in rural and some 
suburban areas is common. In this study, most of the children were from rural and 
suburban areas and consumption non-pasteurized milk was recognized in 17% of 
participants. Our data (Table 13) showed that raw milk probably played small role in 
parasite transmission in our patients. It was not significantly related to seroprevalence of 
toxoplasma gondii infection in bivariate analysis nor was it an independent risk factor in 
logistic regression analysis.   
7.4.2.4. Personal hygiene (hand washing habit) 
Poor hygiene habits at food handling and prior to eating, there also appears to increase 
the probability of human infection (Baril et al. 1999). We didn’t found that personal 
hygiene habits were a risk factor associated with T. gondii seroprevalence in our 
sample. But its effect logically would be related to other risk factors such as contact 
with soil or pets. 
7.4.2.5. Contact with soil 
In agreement with our result contact with soil has been strongly associated with T. 
gondii infections, probably because it is a direct source of oocysts (Spalding et al. 
2005). Contact with soil is difficult to avoid in childhood period, where they carry out 
their play activities. The children were asked to how frequently they washed their hands 
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after having contact soil. Accordingly, children who had contact with soil and not 
always having hand washing practices were 3.46 times at higher risk of infection than 
those who did not have contacts or clean their hands after contact with soil. This 
remained an important independent risk factor within epileptic children, with OR of 
11.3 (95% CI 3.54-36.18) as showed in (Table 26). 
7.4.2.6. Contact with cats  
In Libya, to have cats or dogs as pet is forbidden but there is a relatively high 
population of stray cats. Indeed, 17 % of the total study population reported having cats 
at home. They allow their cats to deposit faeces outside home. Also these cats are fed 
with raw meat and lack routine veterinary care. Most cat owners neglect of preventive 
measures (i.e., washing hands). Contact with cats has not been found to be a risk factor 
as important as contact with cat faeces or soil contaminated with cat’s faeces (Cook et 
al. 2000). In this study, we found that that contact with cats increased the risk of T. 
gondii infection by 2.81-fold. It seems to be a main risk factor (Montoya & Liesenfeld 
2004). Cat ownership and contact with neighbourhood or stray cats near the household 
were strongly associated with infection (Table 14 and 16). This corroborates study 
performed in Brazilian urban children (Dattoli et al. 2011). Presence of neighbourhood 
cats explained most of the effect of “contact with cats” in multivariate analysis; but if 
this variable is omitted in the model other related variables of “contacts with cats” are 
selected. 
7.4.2.7. Contact with dogs 
The role of the dogs and other farmer animals is not entirely clear. However, they may 
act as mechanical vectors (Frenkel and Parker, 1996). Most of the dogs are either stray 
dogs or of farm dogs, as living in a household with a dog is not a common tradition in 
Libya. This explains why child contact with dogs was insignificant in our study and it 
was not related to T. gondii infection. 
7.4.2.8. Source of drinking water 
In Libya it is common for rural households to have wells to extract water for their own 
consumption. Rainwater deposits are also frequent, both in cities and in rural areas. 
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Water from these alternative sources is generally not filtered or chlorinated. However, 
paradoxically, this study has shown that the availability of potable water from wells or 
rainwater reservoirs has been linked to a lower prevalence of Toxoplasma gondii 
infection. This protective effect of drinking water from sources other than the public 
water supply network has been confirmed in both bivariate and multivariate analyses 
(OR 0.37; 95% CI 0.19-0.72). It may be due to its association with some other 
uncontrolled factors, but it must be confirmed in the future. 
In Libya, the public water supply network is mainly based on a complex network of 
large-scale channels and pipelines that carry water extracted from the southern aquifers, 
by means of wells, to the northern coastal cities. This important infrastructure has 
suffered great damage during the difficult situations that have occurred in the country in 
the last recent years. To such an extent, that the provision of potable water in areas of 
Tripoli and other northern cities is often compromised. 
7.4.3. Other factors 
7.4.3.1. Blood transfusion 
Although very uncommon, blood transfusions can cause infection via tachyzoites 
containing blood (Tenter et al. 2000). In Egypt found that more than 50% of blood 
donors have been seropositive for Toxoplasma (Elsheikha et al. 2009). 
In our study, only two of twelve children who had received a blood transfusion, were 
toxoplasma seropositive (17%). This finding is supported by a previous study 
(Nissapatorn et al. 2003).  
7.5. Relations of toxoplasmosis and epilepsy 
Epilepsy is a major chronic neurological disorder burden in developing countries, 
particularly Africa and South America, where a number of infections are also 
predominantly reported as epilepsy aetiology. Parasitic infections are important causes 
of mental and other neurological disorders in these countries (Ngoungou et al. 2015). 
Toxoplasmosis and toxocariasis have been suggested as a significant hazard for epilepsy 
development and needing confirmation. There is limited data available on this topic. 
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The possible impact of toxoplasmosis and its role in the occurrence of epilepsy is not 
well defined up to date. Tissue cysts of toxoplasma are located in numerous anatomical 
sites including the brain. Bradyzoites inside tissue cysts may reactivate, exit cyst, 
transform in tachyzoites and to infect new cells. Toxoplasma gondii inside neurons can 
directly induce changes in neurotransmisors and transmembrane potential which lead to 
triggering seizures (Brooks et al. 2015); or this parasite can to acts indirectly, through 
activation of the immune system and inducing local inflammatory response. Localized 
inflammation may produce microglial scars (granuloma) which may lead to focal 
seizure (Palmer 2007). The alternative explanation to an increased prevalence of T. 
gondii infection in epileptic patients or patients with cryptogenic epilepsy may be that 
these subjects could be more vulnerable or more prone to T. gondii infection (Stommel 
et al. 2001).  
As reviewed in the introduction, a few studies from Israel, USA, Turkey, Iran, Egypt  
and various countries of sub-Saharan Africa investigated the  causal relationship 
between toxoplasma infection and the cryptogenic epilepsy. A total of 13 studies were 
conducted, five studies out of thirteen were reported as a failure to find significant 
relationship between toxoplasmosis and epilepsy as summarized in Table 3. Most of 
these studies had small sample sizes. However, two published meta-analysis exploring 
linkages between toxoplasmosis and epilepsy concluded that this relation does exits 
(Palmer 2007) (Ngoungou et al. 2015).  
Even if there is an indication of link reported between epilepsy and Toxoplasmosis, 
there is uncertainty about whether this involves causality. Uzorka and Arend (2017) 
performed a systematic review of medical literature on this topic and the Bradford Hill 
criteria for causality were used to score selected articles (Höfler 2005). Authors found 
evidence of causality in 3 medical articles, two case reports and one case-control study. 
More definite proof requires further research, e.g. by performing Toxoplasma serology 
in all de novo epilepsy cases (Uzorka & Arend 2017). 
Anti-Toxoplasma IgG antibodies were found in 35.2% in children with cryptogenic 
epilepsy in our study but similar rates of Toxoplasma seropositivity were found in 
symptomatic epileptic patients  (29.4%) and in control subjects (29%).  
This percentage is similar to seroprevalence in epileptic children in the study conducted 
by Ngugi et al. (2013) in Sub-Saharan Africa (35.4%) (Ngugi et al. 2013). In Egypt 
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there are contradictory data about prevalence of toxoplasmosis in epileptic children, 
from 60.6% (El-Tantawy et al. 2013)  to 20% (Eraky et al. 2016). 
Our results did not found direct association between toxoplasmosis prevalence 
and cryptogenic epilepsy, as there was no statistical significant difference between 
patients with cryptogenic epilepsy, symptomatic epilepsy and non-epileptic controls. 
But there were some indirect observations that can support this relation.  
Anti-Toxoplasma IgG titters (Figures 40 and 44) were statistically significantly higher 
in cryptogenic epilepsy patients (27±4.3 IU/ml) than in symptomatic epilepsy patients 
(15.3±5.8 IU/ml) and non-epileptic subjects (16.1±4 IU/ml). Similar results have been 
observed when comparing the percentage of patients with high anti-Toxoplasma IgG 
titers. Percentage of subjects with anti-Toxoplasma IgG >75 IU/ml was higher in 
cryptogenic epilepsy patients (19.4%) than in those with symptomatic epilepsy (6.6%) 
and non-epileptic subjects (6.7%) (Figure 41 and 45). Elevated antibody titers could 
reflect recent infections or could serve as a proxy for estimating the level of exposure, 
as antibody levels would be elevated due to repeated infections or reactivations. 
(Kamuyu et al. 2014). 
Higher titers of anti-toxoplasma IgG were also found in epileptic patients by Stommel et 
al. in US (Stommel et al. 2001) when comparing epileptic adults and healthy controls, 
althoug percentage of seropositivity was not statistically different between both groups.   
Other authors who have studied different neurological abnormalities attributable to 
toxoplasma gondii infection have also found higher IgG titers in studied cases than in 
the controls, although the seroprevalence between cases and controls was not different. 
These results have been obtained when studying the possible relationship of 
toxoplasmosis with psychiatric disorders, schizophrenia and depression (Duffy et al. 
2015) , and work and traffic accidents (Alvarado-Esquivel et al. 2012)(Galván-Ramírez 
et al. 2013)(Flegr et al. 2009). There has been demonstrated a direct relation between 
antibody titers against T. gondii and risk of traffic accidents (Flegr et al. 2002). 
7.5.1.  Type of seizures 
On the basis of the ILAE classification, considering both EEG and clinical data, 93 
patients (63 %) had generalized seizures while 55 patients (37.2%) presented focal 
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seizures. If one patient presented both, partial and generalized seizures it was considered 
as focal seizures. In comparison, focal seizures were less common in patients with 
suspected cryptogenic epilepsy (33.7%), while partial seizures with and without 
secondary generalization was more frequent in symptomatic epilepsy (42.4%).  
Our study showed that seroprevelance of toxoplasmosis was significantly higher in 
children with focal seizures (47.1%) than those with generalized seizures (29%) (Table 
20). After adjusting for the effects of other variables, using a multivariable logistic 
regression model, when the analysis was restricted to patients with cryptogenic and 
symptomatic epilepsy (148 subjects) we found that the association between 
seropositivity to Toxoplasma gondii and focal epilepsy was more strong and significant, 
with an adjusted OR of 2.67 (95% CI: 1.28-5.54; P = 0.009).  
But this increased prevalence of toxoplasma infection in subjects with focal epilepsy 
was seen both in patients with cryptogenic and secondary epilepsy (Figures 51 and 52) 
and in patients with focal epilepsy with abnormal brain MRI (Figure 54). The finding of 
increased seroprevalence of toxoplasmosis in patients with focal seizures diagnosed 
with symptomatic epilepsy or with altered cerebral MRI may suggest two things, either 
this relationship is false or accidental or toxoplasma infection may play an etiological or 
pathogenic role also in the development of epilepsy in some patients with previous brain 
lesions. The finding that toxoplasma infection decreases the epileptogenic threshold in 
laboratory animals could justify this relationship (Babaie et al. 2017).  
On the other hand, most of the lesions diagnosed in the brain MRI were periventricular 
leukomalacia and this was also the most frequent finding in patients diagnosed with 
symptomatic epilepsy and presenting focal seizures (Table 22). Periventricular 
leukomalacia was the only finding in MRI in 8 of the 18 cases of patients with 
symptomatic epilepsy, focal seizures and seropositivity for T. gondii.  
But not all children with periventricular leukomalacia develop seizures; these appear 
only in 26% to 33% of cases; and mainly among those with neonatal seizures, major 
neurological lesions and delayed neurological development (Humphreys et al. 
2007)(Ekici et al. 2013). There is a theoretical possibility that some of these patients 
develop epilepsy for other reasons, but most likely this epilepsy will be blamed on their 
perinatal history if no other cause is demonstrated. 
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There are isolated case reports of focal seizures related to Toxoplasma gondii infection 
(Michałowicz et al. 1989) or as initial manifestation of AIDS related brain 
toxoplasmosis (Özkaya et al. 2006). But it has not been explored in all preceding 
studies, or authors did not report the types of seizures presented (Yazar et al. 
2003)(Babaie et al. 2017)(El-Tantawy et al. 2013)(Ngugi et al. 2013).  
Most studies in industrialized countries have reported a higher proportion of primary 
generalized seizures. In contrast, in developing countries the trend seems to be a higher 
frequency of partial seizures, usually secondarily generalized (Senanayake & Roman 
1993). Taenia solium and T. canis, another parasitic zoonosis, were considered the main 
cause of neurological diseases in developing countries of Latin America, Africa and 
Asia. It has been suggested that both T. solium and T. canis may explain the higher 
incidence of focal epilepsy in developing countries. This significant positive association 
between partial epilepsy and seropositivity of both parasites has been confirmed by two 
case-control studies carried out in rural Bolivia (Nicoletti et al. 2002) and in Burundi 
(Quet et al. 2008).   
7.5.2. Control of seizures 
The main aim of epilepsy therapy is to make the patient totally seizure-free or to reduce 
the duration, frequency and severity. However, More than 10% of patients develop 
medically poor controlled epilepsy (Bourgeois 1995). 
In our study, cryptogenic epilepsy had significantly better control than patients with 
symptomatic epilepsy. Complete seizure control (seizure-free for at least 2 years) to 
antiepileptic drug (AED) was estimated in 15% of patients with cryptogenic epilepsy, 
nearly 23% were with good control (with absence seizure in 6 months) and 40% 
responded partially (some seizures in 6 months). On the other hand in the symptomatic 
epileptic group, there was less than 5 % of complete response; 20 % responded partially 
and well control could be observed in only 5%. There were some differences in number 
of antiepileptic drugs (AED) that received children with symptomatic epilepsy and 
cryptogenic epilepsy. Monotherapy was used in similar frequency, 55.5% in patients 
with symptomatic epilepsy and 58.7% in patient with cryptogenic epilepsy. But 25% of 
patients with symptomatic epilepsy needed three or more drugs, versus 9.8% in the 
cryptogenic epilepsy group.    
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There was no relationship between epilepsy control and T. gondii infection (Table 18). 
A significant relationship was not found when an independent analysis of patients with 
symptomatic epilepsy and cryptogenic epilepsy was performed.  
There are isolated published cases of patients with congenital toxoplasmosis and 
difficult-to-control epilepsy (Jeong et al. 2015)(Rheims et al. 2011). We have not found 
in the medical literature studies on the possible influence of Toxoplasma gondii 
infection in the control of epilepsy with which to compare these results. 
7.6. Final remarks 
Toxoplasmosis is the most prevalent human parasitic infection in the world. Acquired 
toxoplasmosis is considered a banal infection in non-immunocompromised individuals, 
but parasitic tropism by the central nervous system, especially by neurons, has aroused 
the interest of researchers in recent years. 
The possible pathogenic role of toxoplasmosis in the development of epilepsy, 
psychiatric disorders and behavioral changes is still open to debate. In recent years 
important advances have been made on the physiological basis of the epileptogenic 
potential of Toxoplasma gondii in laboratory animals, but their transfer to the clinic in 
humans has not yet occurred. 
The importance of toxoplasmosis as a possible source of epilepsy will depend on the 
prevalence of this infection in each population. It will be low in developed countries and 
in those with low toxoplasmosis prevalence and may be more important in developing 
countries with a high prevalence of this infection. 
 
 
 
  
  
 
120 
 
 
 
 
 
 
STUDY 
LIMITATIONS 
  
  
 
121 
8. STUDY LIMITATIONS 
The present study covered the western area of Libya, as this is the catchment area of the 
National Center for Treatment of Epilepsy and the Tripoli Medical Center. It includes 
the north, the northwest and several regions of south-western Libya. The results shown 
here do not therefore represent the eastern areas of the country. 
Not all eligible patients could be included in the study. Interviews were conducted after 
medical consultations and some patients were unwilling to remain in the hospital to 
participate in the study. In addition, some children could not be included in the study 
because the adults who accompanied them were unaware of some of the birth details 
and perinatal history required for the interview. These are potential sources of selection 
bias. 
On some occasions, the reporting quality of the accompanying adults was low as 
patients and relatives were tired after the consultations. However, it is estimated that 
this was uncommon and did not have an impact in the results of this study  
Our inclusion criteria were based on a commonly used, and standard, definition of 
cryptogenic epilepsy and it is possible that some of them were missed. We have reasons 
to think that among patients considered cryptogenic epilepsy were some who actually 
had symptomatic epilepsy. This adversely affects the study's ability to discriminate 
between the prevalence of Toxoplasma infection between both groups and non-epileptic 
controls. 
Some patients had doubtful titers of IgG anti Toxoplasma gondii, according to the 
reference values of the laboratory that manufactured the Kitts. The correct way to 
resolve this situation is to repeat the analyses with a reference test, such as the Sabin-
Feldman test or immunoblotting. However, it was not possible to repeat the serology of 
doubtful cases.  
In most statistical calculations patients with doubtful titers of antibodies have been 
excluded. Therefore, the total number of cases has been reduced, slightly decreasing the 
contrast power to the tests carried out. 
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9. CONCLUSIONS/CONCLUSIONES 
9.1. CONCLUSIONS 
9.1.1. Introduction 
There are few studies evaluating the association between T. gondii infection and 
epilepsy. These studies show contradictory results, with some finding a positive 
association, while others find no relationship. There are no available data from Europe, 
Latin America, or most Asian countries except Israel, Turkey, and Iran. 
The results presented here, despite the mentioned limitations, indicate that 
toxoplasmosis can be considered a plausible risk factor for epilepsy:  
9.1.2. Conclusions 
 We have not found significant differences in prevalence of T. gondii infection 
between epileptic children and non-epileptic controls. 
 We have not found significant differences in the prevalence of T. gondii 
infection among patients with suspected cryptogenic epilepsy and patients with 
symptomatic epilepsy and controls without epilepsy. 
 Patients with suspected cryptogenic epilepsy presented higher titers of IgG anti 
T. gondii than control groups and a higher percentage of cases with high titers of 
IgG. This may lead to indirect evidence in favour of T. gondii infection being 
able to play a pathogenic role in the development of epilepsy in these patients. 
 Patients with focal epilepsy showed greater prevalence of T. gondii infection 
than patients with other types of seizures and non-epileptic controls. This 
supports that focal epilepsy may be related to T. gondii infection. 
 There was no relation of toxoplasma gondii infection to the degree of control of 
epilepsy. 
 The seroprevalence of T. gondii infection among all studied children, residing in 
western Libya and aged 6 to 18 years, was found to be 29.4% and 5.4% had 
doubtful IgG titers. 
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 Excluding subjects with doubtful IgG titers, the seroprevelance of T. gondii 
infection in studied children with cryptogenic epilepsy, symptomatic epilepsy 
and non-epileptic controls were 35.2%, 29.4% and 29.4% respectively. 
 The risk factors that most strongly were associated with acquired T. gondii 
infection in children were eating uncooked dried meat or undercooked meat, 
eating raw vegetables, contact with soil, contact with cats and the presence of 
neighbourhood cats.  
 Taking drinking water from wells and rain deposits was associated to a 
paradoxical lower prevalence of T. gondii infection. 
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9.2. CONCLUSIONES 
9.2.1. Introducción 
Existen pocos estudios que evalúen la asociación entre la infección por T. gondii y la 
epilepsia. Estos estudios muestran resultados contradictorios, con algunos encontrando 
una asociación positiva, mientras que otros no encuentran ninguna relación. No hay 
datos disponibles de Europa, América Latina ni de la mayoría de los países asiáticos, 
con la excepción de  Israel, Turquía e Irán. 
Basándose en los datos disponibles, con sus obvias limitaciones, sigue siendo apropiado 
considerar la toxoplasmosis como un posible factor de riesgo para el desarrollo de 
epilepsia. 
9.2.2. Conclusiones 
• No hemos encontrado diferencias significativas en la prevalencia de infección por T. 
gondii entre niños epilépticos y controles no epilépticos. 
• No hemos encontrado diferencias significativas en la prevalencia de infección por 
Toxoplasma gondii entre los pacientes con sospecha de epilepsia criptogénica y los 
pacientes con epilepsia sintomática o los controles sin epilepsia. 
• Los pacientes con sospecha de epilepsia criptogénica presentaron mayores títulos de 
IgG anti Toxoplasma gondii que los grupos control y un mayor porcentaje de casos 
con altos títulos de IgG. Esto puede considerarse una evidencia indirecta a favor de 
que la infección por Toxoplasma gondii pueda desempeñar un papel patógeno en el 
desarrollo de epilepsia en estos pacientes. 
• Los pacientes con epilepsia focal mostraron mayor prevalencia de infección por 
Toxoplasma gondii que los pacientes con otros tipos de convulsiones y los controles 
no epilépticos. Esto sugiere que la epilepsia focal puede estar relacionada con la 
infección por Toxoplasma gondii. 
• No hubo relación entre la infección por Toxoplasma gondii y el grado de control de 
la epilepsia. 
• La seroprevalencia de la infección por T. gondii en el grupo completo de niños 
estudiados, residentes en la zona occidental de Libia y con edades comprendidas 
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entre los 6 y 18 años, era del 29,4% y un 5,4% adicional tenían títulos dudosos de 
IgG. 
• Excluyendo a los sujetos con títulos dudosos de IgG, la seroprevalencia de la 
infección por T. gondii en los niños estudiados con epilepsia criptogénica, epilepsia 
sintomática y controles no epilépticos fue del 35,2%, 29,4% y 29,4%, 
respectivamente. 
• Los factores de riesgo que más fuertemente se asociaron con la infección adquirida 
por T. gondii fueron comer carne seca cruda o carne poco cocinada, comer verduras 
crudas, el contacto con el suelo, el contacto con gatos y la presencia de gatos en el 
vecindario. 
• Tomar el agua potable de pozos y depósitos de lluvia se asoció paradójicamente a 
menor seroprevalencia. 
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9.3. Recommendations 
These findings should be checked with studies of larger sample size and with a better 
classification of epileptic patients. More specifically, a careful investigation of the 
personal history, a prospective assessment of the cognitive status of the patients and the 
diagnostic techniques necessary for a correct classification should be carried out. 
Sufficient resources should be available to confirm the serological status of the cases 
with questionable results, repeating studies with reference techniques such as 
immunoblot or Sabin-Feldman. 
These studies should be done in a larger sample to improve our knowledge about the 
risk factors of human exposure to T. gondii, as there were no adequate studies on the 
modes of transmission in Libya. 
The results of the present study indicate the need to implement prevention methods and 
control measures against Toxoplasma infection in Libya. In general, there is a lack of 
awareness about toxoplasmosis, its risk factors and symptom. Adequate health 
education programs are needed, especially among children. Teachers and parents play 
an important role in guiding children to maintain good personal hygiene and healthy 
eating habits. 
Strategies should be designed for the control of stray cats. Improvements in sanitation 
and an epidemiological surveillance policy are needed to avoid an increase in 
toxoplasmosis cases. 
Epileptic children and their families suffer from stigma and discrimination, especially 
women. More attention should be paid to these groups, including psychological, social, 
legal and family support. 
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11. APPENDIX 
I. Informed consent forms 
A. Consent form for CASES  
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English translation: 
Dear Parents 
 
Let me introduce myself, I am Dr Fatima Alshaibani, a PhD student at the University 
Autonoma of Madrid, Spain. I am conducting a study about an infection called 
Toxoplasmosis and how this is linked to epilepsy of unknown origin.  
Your child has been selected to take part in a survey about it for research purposes. 
However knowing if it is common in children with seizure will help us increase 
awareness of the dangers of this illness. Attached is a sheet which describes how this 
infection is acquired and steps of protection. 
We are studying a specific blood test for diagnosis of Toxoplasmasis in order to 
measure how many children have a positive test. We would like to take a small sample 
of your child’s blood to do this and would request you to answer a few questions on the 
history of your child’s illness.  
If you wish to know the test result of your child, you are requested to contact to your 
doctor and he will explains this result for you. 
Whether you participate or not in this study this will not affect your relationship with 
health centre staff and your doctors or the care your child receives.  
Are there any question we can answer to help you better understand the study? 
If you would like your child to join this study please sign in the space below. 
I confirm I received information about the study. 
I wish my children ______________________________ to take part in this study. 
Name of parents/ guardians:    
 
Signature:      
Date: 
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B. Consent form for CONTROLS: 
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English translation:  
Dear Parents 
 
Let me introduce myself, I am Dr Fatima Alshaibani, a PhD student at the University 
Autonoma of Madrid, Spain. I am conducting a study about an infection called 
Toxoplasmosis and how this is linked to epilepsy of unknown origin.  
Your child has been selected to take part in a survey about it for research purposes. 
However knowing if it is common in children with seizure will help us increase 
awareness of the dangers of this illness. Attached is a sheet which describes how this 
infection is acquired and steps of protection. 
We are mainly studying children with epilepsy, but need a sample of children without 
epilepsy to find out if they have chance of getting this infection. These are control 
children and your child is in that group. We would like to take a small sample of your 
child’s blood to do this and would request you to answer a few questions on the history 
of your child’s illness. We are studying a specific blood test for diagnosis of 
Toxoplasmasis in order to measure how many children have a positive test. We would 
like to take a small sample of your child’s blood to do this and would request you to 
answer a few questions on the history of your child’s illness.  
If you wish to know the test result of your child, you are requested to contact Head of 
infectious disease department and they will explains this to you. 
Whether you participate or not in this study this will not affect your relationship with 
health centre staff and your doctors or the care your child receives.  
Are there any question we can answer to help you better understand the study? 
If you would like your child to join this study please sign in the space below. 
I confirm I received information about the study. 
I wish my children ______________________________ to take part in this study. 
Name of parents/ guardians:       
Signature:     
Date: 
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II. Questionnaires 
A. Questionaries’ for epileptic children 
I.A Questioner 
A controlled study of anti-Toxoplasma antibody prevalence in Libyan                     
epileptic children 
For cases 
Number of questioner: 
Name of childe: 
Date of birth (age):  
Sex of childe   
Male                             Female  
Residence   
Urban                        Suburban                           Rural   
 
A) Child past history of:  
1. Blood transfusion:   
2. Ingestion of raw meat:   
3. Source of drinking water:       Main supply                            
                                                  Other source   
4. Drinking milk:      Raw unpasteurized milk                             
  Pasteurized milk                  
5. Eating raw meat:                                     
6. Contact with soil:   
7. Good personal hygiene :  
8. Contact with cat:  
9. House cat                
10. Neighborhoods cats                          
11. Number of cats at home             
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B) History of seizure  
1. Age onset: 
2. Frequency in last 6 month: 
3. Type of seizure:  
4. Type of treatment:   
5. Result of EEG:              CTSCAN:            MRI:   
 
 
 
 
 
 
 
 
C) PERI/POSTNATAL HISTORY   
1. Gestation age:                           
2. Perital history:  
3. Postnatal history:  
 
 
D) Neuro development history   
 1. Neurological impairment:  
 2. Age of starting walk: 
 3. Age of starting speech:  
 4. History of speech disorder:    
 5. Attending school:  
 6. Age appropriate school:  
 7. History of learning disability:  
 
 
E) Antibody test result       
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B. Questionaries’ for controls 
 
I.B Questioner 
A controlled study of anti-Toxoplasma antibody prevalence in Libyan                     
epileptic children 
For control 
Number of questioner: 
Name of childe: 
Date of birth (age):  
Sex of childe   
Male                             Female  
Residence   
Urban                        Suburban                           Rural   
 
A) Child past history of:  
1. Blood transfusion:   
2. Ingestion of raw meat:   
3. Source of drinking water:       Main supply                            
                                                  Other source   
4. Drinking milk:      Raw unpasteurized milk                             
  Pasteurized milk                  
5. Eating raw meat:                                     
6. Contact with soil:   
7. Good personal hygiene :  
8. Contact with cat:  
9. House cat                
10. Neighborhoods cats                          
11. Number of cats at home             
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C) PERI/POSTNATAL HISTORY   
1. Gestation age:                           
2. Perital history:  
3. Postnatal history:  
 
 
 
 
D) Neuro development history   
1. Neuro logical impairment:  
 
 
 
 2. Age of starting walk: 
 3. Age of starting speech:  
 4. History of speech disorder:  
 5.  Attending school:  
 6. Age appropriate school:  
 
 
 7. History of learning disability:  
 
 
E) Antibody test result        
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III. Informative sheet 
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